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The opioid antagonist naloxone has a special place in pharmacology – it has no intrinsic
action of its own, but it is able to save lives in the case of life threatening side-effects
caused by other drugs. Naloxone is an antagonist for all opioid receptors, but most
specifically for the µ-opioid receptor, which is the receptor through which opioids such
as morphine and fentanyl exert their effects. Those effects include first and foremost
analgesia, but also nausea and vomiting, sedation and life-threatening respiratory de-
pression. It is in the case of the latter effect that naloxone can be life-saving, as it is
able to reverse respiratory depression.
Paradoxically, naloxone, as an antagonist, was a side product of the search for an opioid
agonist, one without addictive properties. For many centuries, the addictive properties
of opium (and later morphine) were the cause of severe medical and social problems.
However, there was (and still is) no alternative to morphine when it comes to analge-
sia. The solution to this problem was expected to come in the form of a non-addictive
opioid agonist and since the start of the twentieth century, scientists have been working
to find such a compound. This search has been fruitless with regard to a non-addictive
opioid agonist, but has produced several opioid antagonistic drugs.
Minor alterations to a drug’s chemical structure can change an agonist into an an-
tagonist. The first opioid antagonist, N-allylnorcodeine was discovered in 1915, by
changing a methyl group in the codeine molecule to an allyl group.1 After this discov-
ery, however, the research in non-addictive opioids lay dormant for a while and it would
take until 1944 for a second member of the opioid antagonist class, N-allylnormorphine
(or nalorphine), to be characterized. Nalorphine showed antagonism for morphine in-
duced respiratory depression,2 but was later found to be a µ-opioid receptor agonist as
well, with severe dysphoric side-effects (due to its agonism of the κ-opioid receptor).3
Further experimentation with nalorphine’s chemical structure finally yielded N-allyl-
noroxymorphone, or naloxone, in 1960.4
1.2 Respiration
Naloxone is best known for its use in opioid induced respiratory depression and it is
therefore that the first part of this thesis is dedicated to its use in respiratory studies.
Opioid induced respiratory depression is clinically recognized by an increase in arterial
PCO2 .
5 This is caused by a reduction of both tidal volume and respiratory frequency,
which is in turn caused by activation of the µ-opioid receptors in the respiratory control
centers of the central nervous system.6 This µ-opioid receptor activation leads to a
decreased sensitivity of the chemoreceptors, characterized in a right and downward shift
of the V̇i-PET,CO2-response curve. In other words, opioids cause the chemoreceptors to
be less sensitive to carbon dioxide (CO2), which is one of their main stimuli. Naloxone
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can antagonize this effect through competitive antagonism at the µ-opioid receptor and
is thus able to save lives by reversing respiratory depression. It is always important to
keep resuscitated patients under surveillance, as naloxone’s duration of action is often
shorter than that of the opioid. This means that renarcotization can occur easily,
especially with longer acting opioids such as morphine, heroin and methadone. The
duration of naloxone’s reversal is highly dependent on the opioid used, and therefore
it is important that we characterize naloxone’s behaviour in different opioids.
1.3 Pain and hyperalgesia
Essentially, pain is a physiological signalling system: it alerts the brain that something
is wrong in the body and thus urges the body to protect itself from further harm. There
is a purely physical component to pain, called nociception. This is the conduction of a
signal from a nociceptor (a receptor responsive to painful stimuli) or a damaged nerve
in the peripheral nervous system on to the central nervous system.7 But nociception
alone is not pain. Pain also has an emotional component, which consists of our re-
sponse to a painful stimulus. This response is highly variable and depends on both
individual and cultural factors.8 Analgetic drugs, such as opioids, influence one or both
of these components and thus cause us to feel less pain. Opioids are renowned for their
analgetic qualities – they still form the gold standard in pain therapy. Less recognized
is that they may also increase pain sensitivity.
This so-called ‘Opioid induced Hyperalgesia’ (OIH) has proven to be a growing problem
in pain management and has therefore been the focus of much research over the past
decade.9 OIH can in general be defined as an increased pain response due to the use
of opioids.10 For a long time, OIH has been mistaken for opioid tolerance, as both
conditions require higher opioid dosing. But at present the general hypothesis is that
OIH may be the result of an central sensitization process.11 This is probably caused by
activation of N-methyl-D-aspartate (NMDA) receptors. Heightened activity of protein
kinase C removes the magnesium ‘lock’ off the NMDA-receptor, thereby activating the
receptor. This ultimately leads to a higher pain perception. It has been suggested
that µ-opioid receptor activation could activate protein kinase C.12 If naloxone could
prevent this activation, it could perhaps be used in the prevention and treatment of
opioid induced hyperalgesia.
1.4 Addiction
Opioid addiction remains a social and medical problem. Initial attempts to manufac-
ture an opioid without addictive properties were in vain. The obvious solution was
then to try and block the µ-opioid receptor, using opioid antagonists such as nalox-
one.13 This causes acute withdrawal syndrome in opioid dependent patients, which can
either be a goal of the therapy (in detoxification settings) or a threatening side-effect
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(after an opioid overdose).14 Due to its short elimination half-life, naloxone is not the
first choice in maintenance therapy for opioid dependent patients.15 It is however most
famous for its use in the treatment of opioid overdose. Patients overdosing on heroin
have a severe respiratory depression, which often results in a comatose state. In those
patients, naloxone can make the difference between life or death.
1.5 Aims
With its antagonism of the µ-opioid receptor, there are several applications of naloxone
worth investigating. This thesis is specifically aimed to answer the following questions:
• In chapters 2, 3 and 4, the possibility to reverse opioid-induced respiratory de-
pression with naloxone, is explored and the question whether this differs between
different opioids is studied.
• In chapter 5, the question is addressed whether naloxone can be used to abolish
opioid induced hyperalgesia.
• Chapter 6 is an elaboration upon the roles naloxone can play in the treatment of
opioid addiction.
References
1. Archer S: ‘Historical perspective on the chem-
istry and development of naltrexone.’ NIDA
Res Monogr, 28:3–10, 1981.
2. Hart E and McCawley E: ‘The pharmacology
of N-allylnormorphine as compared with mor-
phine.’ J Pharmacol Exp Ther, 82:339–348,
1944.
3. Lasagna L and Beecher HK: ‘The analgesic
effectiveness of nalorphine and nalorphine-
morphine combinations in man.’ J Pharmacol
Exp Ther, 112(3):356–363, 1954.
4. Howland MA: ‘Opioid antagonists’. In Gold-
frank LR, ed., Goldfranks’ toxicological emer-
gencies, Appleton & Lange, 1998.
5. Dahan A: ‘Respiratory pharmacology’. In
Healey T and Knight P, eds., Wylie and
Churchill-Davidson’s A practice of anesthesia,
7th edn., Hodder Arnold, 2003.
6. Dahan A and Teppema LJ: ‘Influence of
anaesthesia and analgesia on the control of
breathing.’ Br J Anaesth, 91(1):40–49, 2003.
7. Basbaum A and Jessel T: ‘The perception of
pain’. In Kandel E, ed., Principles of neural
science, 4th edn., McGraw Hill, 2000.
8. Johnstone RE and Fife T: ‘Ambivalence to-
ward pain: Schweitzer versus Nine Inch
Nails.’ Anesthesiology, 82(3):799–800, 1995.
9. Angst MS and Clark JD: ‘Opioid-induced hy-
peralgesia: a qualitative systematic review.’
Anesthesiology, 104(3):570–587, 2006.
10. ‘International Association for the Study of
Pain’, 2009, http://www.iasp-pain.org/.
Accessed 2 February 2009.
11. Mao J: ‘Opioid-induced abnormal pain sensi-




12. Simonnet G and Rivat C: ‘Opioid-induced hy-
peralgesia: abnormal or normal pain?’ Neu-
roreport, 14(1):1–7, 2003.
13. Martin W: ‘Naloxone’. Ann Intern Med,
85(6):765–768, 1976.
14. Gowing L and Ali R: ‘The place of detoxifica-
tion in treatment of opioid dependence’. Cur-
rent Opinion in Psychiatry, 19(3):266–270,
2006.
15. Van Dorp E, Yassen A and Dahan A:
‘Naloxone treatment in opioid addiction: the






Differential effect of morphine and
morphine-6-glucuronide on the control of
breathing in the anesthetized cat
Luc J. Teppema, Eveline L.A. van Dorp, Babak Mousavi Gourabi, Jack W. van Kleef
& Albert Dahan
Anesthesiology 2008; 109: 689–697
Antagonism of opioid induced respiratory depression in cats
2.1 Introduction
In animals and humans, morphine’s metabolite, morphine-6-glucuronide (M6G), acti-
vates the µ-opioid receptor causing typical opioid behaviour.1–3 This includes analge-
sia (or antinociception), miosis, respiratory depression and nausea/vomiting. M6G is
present in the blood of patients after just a single dose of morphine but its contribu-
tion to morphine analgesia and toxicity (e.g., sedation and respiratory depression) only
becomes significant after long-term morphine treatment and/or in patients with renal
impairment (as the primary route of M6G clearance is via the kidneys).4–7 Several
studies by Pasternak and co-workers indicate the existence of a unique M6G receptor
responsible for its analgesic activity. First of all, in morphine-insensitive mice, M6G
analgesia is uncompromized8 and M6G shows no analgesic cross-tolerance in mice made
tolerant to morphine.8 Furthermore, studies into labelled M6G binding to bovine tis-
sue indicate the existence of a high and a low affinity component. The low-affinity
component corresponds to labelling of traditional µ-opioid receptors, while the high-
affinity component shows selectivity to M6G.9,10 More evidence for a separate M6G
receptor comes from another study, in which 3-methoxynaltrexone (3mNTX) is an
opioid receptor antagonist selective for the M6G binding site. In CD-1 mice and rats,
3mNTX displaces the M6G dose-response (analgesia) curve without affecting the curve
for morphine.10,11 Finally, rats treated with antisense probes against exon 1 of the µ-
opioid receptor gene (Oprm1 ) display reduced morphine analgesia but normal M6G
analgesia. Similar observations were made for probes targeting specific G-protein α
subunits8,12,13 and for Oprm1 gene knockout mice. The evidence from these last stud-
ies is less compelling, as Oprm1 gene knockout mice do not display any G-protein
activation.14 Furthermore, the effect of M6G analgesia in this mouse strain was not
reproduced by others.15 Interestingly, the M6G opioid receptor seems equally sensitive
to heroin.8–13,16
Animal and human studies indicate that M6G produces less respiratory depression than
morphine at equi-antinociceptive/analgesic doses.17–19 This is an important feature of
a potent opioid analgesic, as respiratory depression is a potentially lethal side effect of
acute opioid administration.20 Possibly, the different effects of M6G and morphine on
respiration reflects activation of distinct µ-opioid receptors with different effects on the
ventilatory control system. The current study was designed to quantify the respiratory
effects of M6G versus morphine and to assess whether the effect of M6G is related to
the earlier classified unique M6G-receptor. We initially measured the effects of mor-
phine and M6G on the dynamic ventilatory response to carbon dioxide (CO2) in the
anesthetized cat and next investigated the effect of the M6G-receptor selective antago-
nist 3mNTX on respiratory depression induced by morphine and M6G. The ventilatory
responses were analysed using a two-compartment model of the respiratory controller,
reflecting the peripheral and central chemoreflex pathways.21–24 These studies provide
information about the sites of action of M6G, morphine and 3mNTX with respect to
their dynamic and steady-state effects on the ventilatory CO2 response curves.
13
Chapter 2
2.2 Materials and Methods
The experiments were performed after approval of the protocol by the local Ethical
Committee for Animal Experiments (UDEC, Leiden University Medical Center, The
Netherlands). Eighteen purebred (European shorthair) cats (eight males/ten females;
mean (± SD) body weight 3.3 kg ± 1.0 kg) were sedated with 10 mg/kg intramuscular
ketamine hydrochloride. Next, the animals were anesthetized with a gas containing
0.7 to 1.4% sevoflurane and 30% oxygen (O2) in nitrogen (N2). The right femoral
vein and artery were cannulated, after which 20 mg/kg α-chloralose and 100 mg/kg
urethane were slowly administered intravenously. Subsequently the volatile anesthetic
was withdrawn. Approximately one hour later, an infusion of an α-chloralose-urethane
solution was started at a rate of 1.0 to 1.5 mg·kg−1·h−1 α-chloralose and 5.0 to 7.5
mg·kg−1·h−1 urethane. This regimen leads to conditions in which the level of anesthe-
sia is sufficient to suppress pain withdrawal reflexes but light enough to preserve the
corneal reflex. The stability of the ventilatory parameters was studied previously, and
they were found to be similar compared to those in awake animals, and to be stable
over a period of at least six hours.24–26 We use a feline experimental model as it al-
lows the application of the dynamic end-tidal forcing technique which is an important
requirement for studying ventilatory control in a reliable fashion. A second argument
for using this technique is that cat data are often easily comparable to human data.
To measure inspiratory and expiratory flow, the trachea of the animals was cannulated
and connected to a Fleisch Nr. 0 flow transducer (Fleisch, Lausanne, Switzerland),
which was attached to differential pressure transducer (Statham PM197, Los Angeles,
CA, USA). The flow transducer was connected to a T-piece of which one arm received a
continuous fresh gas flow of 5 l·min−1. Three computer-controlled mass flow controllers
(Bronkhorst High-Tech, Veenendaal, The Netherlands) composed desired inspiratory
gas mixtures of O2, CO2 and N2. The inspiratory and expiratory fractions of O2 and
CO2 were measured with a Datex Multicap monitor (Datex-Engstrom, Helsinki, Fin-
land). The temperature of the animals was controlled within 1 ◦C and ranged among
cats between 38 and 39 ◦C. All signals were recorded digitally (sample frequency 100
Hz) and stored on a breath-to-breath basis on a computer for further analysis.
Study Design
The dynamic ventilatory response to CO2 was studied with the Dynamic End-tidal
Forcing (DEF) technique.21–24,27 Step-wise changes in end-tidal PET,CO2 at a constant
end-tidal PET,O2 (110 mmHg) were applied. Each DEF run started with a steady-
state period of 2 minutes during which PET,CO2 was maintained at 4 mmHg above
resting values. Thereafter, the PET,CO2 was elevated by 7.5 mmHg for 7 minutes and
then lowered to the initial value and kept constant for another 7 minutes. In order to
avoid irregular breathing at PET,CO2 values close to the apneic threshold, we adjusted
a clamped baseline PET,CO2 at a level approximately 3-4 mmHg higher than the apneic
14
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threshold during any given experimental condition (i.e., in control and after each drug
infusion).
Initially, the effect of four cumulative M6G doses (0.15 mg/kg, 0.3 mg/kg, 0.6 mg/kg
and 0.9 mg/kg) followed by two cumulative 3mNTX doses (0.1 and 0.2 mg/kg) on
ventilation, with PET,CO2 clamped 4 mmHg above resting, was tested in two cats. This
was done to determine the M6G and 3mNTX doses to be used. Next, we performed
three separate studies.
Study 1 In this study, the effect of the intravenous infusion of morphine (0.15 mg/kg)
followed by 3mNTX (0.2 mg/kg iv) and subsequently M6G (0.8 mg/kg iv) on the
dynamic ventilatory response to CO2 was assessed in six cats.
Study 2 Here, we obtain ventilatory CO2 responses in six cats after the iv infusion
of M6G (0.8 mg/kg), followed by 3mNTX (0.2 mg/kg iv) and lastly morphine (0.15
mg/kg iv).
Study 3 Finally, the effect of just 3mNTX (0.2 mg/kg iv) was assessed in four cats.
In all studies, three to four control DEF runs were obtained prior to any drug infusion
(control runs); after each drug infusion and a pause of about 20–30 minutes, two to
four DEF runs were performed. M6G was obtained from CeNeS Ltd. (Cambridge,
United Kingdom), morphine from Pharmachemie BV (Haarlem, The Netherlands),
and 3mNTX from Sigma BV (Zwijndrecht, The Netherlands).
Data and Statistical Analysis
The steady-state relation between inspired minute ventilation (V̇i) and PET,CO2 is linear
down to apnea and described by:21–24,27
V̇i = (Gc + Gp) · (PET,CO2 − B)
with Gc: sensitivity of the central chemoreceptors
Gp: sensitivity of the peripheral chemoreceptors
B: apneic threshold (extrapolated PET,CO2 at V̇i= 0 l · min
−1).
When applying rapid changes in end-tidal PCO2 at constant end-tidal PO2 it is possible
to quantify the contributions of the peripheral and central chemoreflex loops to total
ventilation. This is based on the difference in response times and dynamics of the two
chemoreflexes in response to a change in end-tidal PCO2 .
21–24
The central chemoreflex loop displays a relative large time delay (average response time
in the cat is 8 s) with slow dynamics (average time constant in the cat is 100 s); the
response time of the peripheral chemoreflex loop is on average 4 s with a time constant
of about 10 s.21,22,24 To estimate Gc, Gp and B, we fitted the ventilatory responses
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Figure 2.1: Effect of four cu-
mulative M6G doses, followed
by 2 cumulative 3mNTX doses
on resting ventilation in one
cat. The data were obtained
at a clamped PET,CO2 of 45
mmHg. Only at M6G doses
of 0.6 mg/kg and higher was
a reduced response to CO2 ob-
served (data not shown).
to a two-compartmental model using a least-squares fitting routine as described previ-
ously.21–24 In the fitting procedure parameters Gp and B were not restricted to values
equal to or greater than zero. Occasionally a negative optimal value for Gp was ob-
tained which then was set to zero in the statistical analysis.
Initially the data were tested for normality using the Kolmogorov-Smirnov test. As all
data were normally distributed, to determine the level of significance of the treatment
effects, we next performed an analysis of variance on the group data. A separate
analysis was performed on the data from studies 1, 2 and 3. Post-hoc comparisons
were made with the Bonferroni-test. In order to correct for multiple comparisons, P-
values < 0.05 were considered significant. The analysis was performed using SPSS 14.0
for Windows (SPSS, Inc., Chicago, IL, USA). Values reported are means ± SD.
2.3 Results
The M6G and 3mNTX doses used in the study were based on the effects of increment-
ing doses of the two drugs on resting ventilation as observed in two cats (see figure 2.1
for the results in one animal). M6G produced a dose-dependent depression of resting
ventilation. The M6G dose causing a depression similar to that observed with 0.15
mg/kg morphine20,21,23 was 0.8 mg/kg. We therefore used an M6G dose of 0.8 mg/kg
in the subsequent studies. 3mNTX produced no effect at 0.1 mg/kg but displayed full
reversal of the depressed resting ventilation at a dose of 0.2 mg/kg.
To get an appreciation of the quality of the DEF experiments and data fits, we plot-
ted four examples obtained in one cat from study 2 in figure 2.2. The top diagrams
show the applied steps into and out of end-tidal PCO2 . In the bottom graphs, each
dot represents one breath. The slow central (Vc) and fast peripheral (Vp) components
are shown, together with the least-squares model fits (the thick lines through the data
points). As can be seen by visual inspection, the model adequately describes the data.
In these examples, M6G increased the apneic threshold (B) and reduced the ventilatory
CO2 sensitivity of the peripheral chemoreflex loop (Gp) without affecting the ventila-





























































































































Figure 2.2: Example of the dynamic ventilatory responses to end-tidal partial pressure of CO2 (PET,CO2) and data fits in one cat. One control
response (A), one response after 0.8 mg/kg morphine-6-glucuronide (M6G; B), one response after a subsequent dose of 3-methoxynaltrexone
(3mNTX; C), and one response after a subsequent dose of 0.15 mg/kg morphine (D) are shown. The top panels show the input function to the
system (i.e., PET,CO2). In the lower panels, each open circle represents one breath. The line with the fast dynamics is the estimated output of
the peripheral chemoreflex loop (Vp); the thin line with the slow dynamics is the estimated output of the central chemoreflex loop (Vc). The
sum of Vp and Vc is the thick line through the data points. Parameter values for the shown data fits are as follows: (A) apneic threshold =
23.6 mmHg, central CO2 sensitivity = 0.13 l·min
−1·mmHg−1, peripheral CO2 sensitivity = 0.020 l·min
−1·mmHg−1; (B) apneic threshold = 28.7
mmHg, central CO2 sensitivity = 0.13 l·min
−1·mmHg−1, peripheral CO2 sensitivity = 0.011 l·min
−1·mmHg−1; (C) apneic threshold = 22.8 mmHg,
central CO2 sensitivity = 0.13 l·min
−1·mmHg−1, peripheral CO2 sensitivity = 0.04 l·min
−1·mmHg−1; (D) apneic threshold = 22.5 mmHg, central
CO2 sensitivity = 0.16 l·min




3mNTX caused the return of apneic threshold to control values and increased periph-
eral CO2 sensitivity to values greater than control. Finally, the infusion of morphine
after 3mNTX did not further influence any of the model parameters.
Study 1 In the 6 cats of study 1 we performed 22 control experiments, 20 after
morphine, 19 after 3mNTX and 16 after M6G. Treatment effects were observed on
the apneic threshold, central and total CO2 sensitivities with no effects on peripheral
CO2 sensitivity and the ratio peripheral/central CO2 sensitivity (figure 2.3). Morphine
caused a significant increase of the apneic threshold from 27.5 ± 3.6 mmHg to 31.5
± 2.2 mmHg, and reduced the central and total CO2 sensitivities from 0.13 ± 0.06
to 0.07 ± 0.04 and from 0.16 ± 0.07 to 0.08 ± 0.04 l·min−1·mmHg−1, respectively (P
< 0.01). After the infusion of the opioid antagonist 3mNTX the apneic threshold
reduced to values below baseline (24.8 ± 2.5 mmHg), central CO2 sensitivity increased
to a value in between morphine and M6G (0.11 ± 0.04 l·min−1·mmHg−1) and total
CO2 sensitivity returned to control values (0.11 ± 0.05 l·min
−1·mmHg−1). Infusion of
M6G after 3mNTX had no further effect on any of the model parameters.
Study 2 In the 6 cats of study 2 we performed 27 control experiments, 17 after
M6G, 18 after 3mNTX and 17 after morphine. Treatment effects were observed for all
model parameters except central CO2 sensitivity (figure 2.4). M6G caused a significant
increase of the apneic threshold from 26.3 ± 5.7 mmHg to 34.2 ± 25.0 mmHg, and
reduced the peripheral and total CO2 sensitivities from 0.031 ± 0.013 to 0.013 ± 0.017
l·min−1·mmHg−1 and from 0.16 ± 0.02 to 0.13 ± 0.05 l·min−1·mmHg−1, respectively
(P < 0.01). The ratio peripheral/central CO2 sensitivity was reduced from 0.26 ± 0.13
to 0.09 ± 0.13. Infusion of the opioid antagonist after M6G caused full return to
baseline levels of the apneic threshold (26.5 ± 5.1 mmHg), the peripheral and total
CO2 sensitivities (0.024 ± 0.017 and 0.17 ± 0.05 l·min
−1·mmHg−1, respectively), and
the ratio peripheral/central CO2 sensitivity (0.18 ± 0.11). Infusion of morphine after
3mNTX had no further effect on any of the model parameters.
Study 3 In the 4 cats of study 3, we performed 30 experiments (15 control and 15
after 3mNTX). Infusion of 0.2 mg/kg 3mNTX had no systematic effect on any of the
estimated model parameters (figure 2.5).
2.4 Discussion
Morphine (0.15 mg/kg) affects the control of breathing by increasing the apneic thresh-
old and by reducing central ventilatory CO2 sensitivity. These effects are fully antag-
onized by 3mNTX and subsequent infusions of M6G are without further effect. M6G
(0.8 mg/kg) on the other hand, causes an increase of the apneic threshold together
with a reduction of the peripheral CO2 sensitivity without affecting central CO2 sen-
















































































































































C MOR 3mNTX M6G
Figure 2.3: Study 1: Effect of morphine (MOR) followed by 3-methoxynaltrexone (3mNTX) and morphine-6-glucuronide (M6G) on apneic
threshold (B; figure A), central CO2 sensitivity (Gc; figure B), peripheral CO2 sensitivity (Gp; figure C), total CO2 sensitivity (sum of peripheral
and central CO2 sensitivity; figure D), and ratio of peripheral to central CO2 sensitivity (figure E). Data were obtained in six cats. Values are the
mean of the cat means ± SD. Treatment effects were obtained for apneic threshold (P < 0.001), central CO2 sensitivity (P < 0.001), and total













































































































C M6G 3mNTX MOR
*
Figure 2.4: Study 2: Effect of morphine-6-glucuronide (M6G) followed by 3-methoxynaltrexone (3mNTX) and morphine (MOR) on apneic
threshold (B; figure A), central CO2 sensitivity (Gc; figure B), peripheral CO2 sensitivity (Gp; figure C), total CO2 sensitivity (Gtot; sum of
peripheral and central CO2 sensitivity; figure D), and ratio of peripheral to central CO2 sensitivity (Gp/Gc; figure E). Data were obtained in six
cats. Values are the mean of the cat means ± SD. Treatment effects were observed for apneic threshold (P < 0.001), central CO2 sensitivity (P =
0.01), peripheral CO2 sensitivity (P = 0.001), total CO2sensitivity (P < 0.001), and ratio of peripheral to central CO2 sensitivity (P = 0.001). *
P < 0.01 versus control and 3mNTX. C = control.
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loop. These effects of M6G are fully antagonized by 3mNTX and subsequent infusions
of morphine are without further effects. Finally, 3mNTX (0.2 mg/kg) has no effect
on the apneic threshold and the peripheral and central CO2 sensitivities when given
without prior opioid infusion.
We used a M6G dose that was 5.3 times greater than the morphine dose. The M6G
dosing was based on our pilot experiments in two cats showing that at 0.8 mg/kg M6G
causes a reduction in resting ventilation of similar magnitude as 0.15 mg/kg morphine.
This observation was later confirmed: the morphine and M6G ventilatory CO2 response
curves intersect at 38 mmHg (just above the metabolic hyperbola), a value close to
the mean clamped end-tidal PCO2 value in our study (figure 2.6). In contrast to our
observation of greater morphine potency, animal studies usually show that M6G is
the more potent drug with respect to antinociception (cf. Kilpatrick and Smith3 and
references cited therein) and respiratory depression. For example, in mice, rats, dogs
and neonatal guinea pigs morphine:M6G potency ratios for respiratory depression vary
from 1:4 after intraperitoneal or intravenous injections to 1:10 after intracerebroven-
tricular injection.28–31 Apparently the cat forms an exception to this rule which may
be related to the absence of an effect on the CO2 sensitivity of the central chemoreflex
loop, the major component of total chemical drive.
In the present study morphine had no effect on the peripheral CO2 sensitivity (see figure
2.3). This contrasts with earlier studies on morphine using a similar cat model,21,22,27 as
well as with our observation that morphine failed to affect the ratio peripheral/central
CO2 sensitivity (Gp/Gc, figure 2.3). This latter observation together with the reduc-
tion of central CO2 sensitivity suggests an effect of morphine on neuronal structures
common to both the peripheral and central chemoreflex pathway (such as the respira-
tory centers in the ventrolateral medulla). Some effect of morphine on the peripheral
chemoreflex is expected. There are indications for the presence of opioid-receptors in
cat carotid bodies: 98% of type I carotid body cells exhibit enkephalin immunoreac-
tivity,32 and naloxone enhances the response to hypoxia as measured from single or
paucifiber preparations of carotid body afferents.33 With the above taken into account,
we believe that our current study may have been underpowered to observe a morphine
effect on the peripheral CO2 sensitivity (P = 0.07 versus control). However, we cannot
exclude that study-differences in the effect of morphine on the peripheral chemoreflex
loop are also partly related to differences in the genetic background of the cats we
used in our studies: mongrel cats in our previous studies versus inbred animals in the
current study.21,22,27
Compared to morphine, M6G showed important differences in its effect on ventilatory
control. At the relatively high dose tested, M6G increased the apneic threshold by
8 mmHg, while the peripheral CO2 sensitivity decreased by more than 60% without
any effect on central CO2 sensitivity (morphine reduced the central CO2 sensitivity by











































































































Figure 2.5: Study 3: Effect of 3-methoxynaltrexone on apneic threshold (B; A), central CO2 sensitivity (Gc; B), peripheral CO2 sensitivity (Gp;
C), total CO2 sensitivity (Gtot; sum of peripheral and central CO2 sensitivity; D), and ratio of peripheral to central CO2 sensitivity (Gp/Gc; E).
Data were obtained in four cats. Data are the mean of the cat means ± SD. C = control, 3mNTX = 3-methoxynaltrexone.
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Figure 2.6: Effect of 0.15 mg/kg
morphine and 0.8 mg/kg morphine-6-
glucuronide (M6G) on the ventilatory re-
sponse to CO2. The control response
is also given. During anesthesia, rest-
ing ventilation occurs at the intersec-
tion of the ventilatory CO2 response
curve and the metabolic hyperbola (M).
While resting ventilation did not differ
between the two drugs, the end-tidal par-
tial pressure of CO2 (PET,CO2) to reach
a ventilation level of 2 l·min−1 was 7
mmHg (approximately 1 vol%) greater
for morphine than for M6G (50 versus 57
mmHg). This is an indication that M6G
produces less respiratory depression than
morphine at the drug doses used.
ence in respiratory behaviour between the two opioids. In contrast to morphine, M6G
may not have crossed the blood-brain barrier in sufficient amounts but exerted its effect
at the carotid bodies. M6G is much more polar than morphine,34 and consequently
passes the blood-brain barrier much slower than morphine.35 However, at the dose used
and the relatively low volume of distribution and clearance, there will be a large M6G
concentration gradient across the blood-brain barrier.36 This will result in sufficient
passage of M6G into the brain to cause a central effect. Furthermore, although opioid
receptors are assumed to exist in the carotid body (see paragraph above) there are
no studies that directly demonstrate the actual existence of µ-opioid receptors in the
carotid chemoreceptors. Of interest to our discussion is the observation that in our
anesthetized cat model, we were unable to observe an effect of morphine (0.15 mg/kg)
on the steady-state ventilatory response to hypoxia.22 In humans, an experimental opi-
oid that does not cross the blood-brain barrier has no effect on the ventilatory response
to acute hypoxia,37 while intrathecal morphine has a profound and long-lasting effect
on this same response.38 In summary, we suggest that an appreciable amount of the
M6G that we infused did cross the blood-brain barrier and consequently may have
affected the ventilatory control system for a large part at central sites (i.e., within the
central nervous system).
Another possibility for the observed differences between morphine and M6G is that
while morphine acts at the classical µ-opioid receptor, ubiquitously present on the neu-
ronal substrates of the ventilatory control system, M6G acts at the proposed unique
M6G receptor,8–13,16 which is then present in the peripheral chemoreflex pathways
and/or brainstem neurons that control the apneic threshold but not within the central
chemoreflex pathway. An important feature of this opioid receptor system is its se-
lective antagonism by 3mNTX.10,11 However, we were unable to demonstrate 3mNTX
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selectivity for M6G-induced respiratory depression. 3mNTX antagonized both mor-
phine and M6G-induced respiratory changes and administration of either opioid after
3mNTX was without effect. One can contend that we missed a distinctive effect of
3mNTX between morphine and M6G because we did not perform dose-response stud-
ies. There are however strong arguments to dismiss this suggestion. In mice intracere-
broventricular infusion of 2.5 ng 3mNTX significantly lowered the analgesic actions of
M6G without affecting morphine analgesia (see fig. 2 of Brown et al.10). Five to six
times higher doses of 3mNTX were required to reduce morphine analgesia to the same
effect.10 We observed that at the lowest dose at which 3mNTX caused full reversal of
M6G respiratory effect (0.2 mg/kg) full reversal of morphine respiratory effect already
occurred. Since the dose-response of 3mNTX appeared to be very steep (no effect at
0.1 mg/kg; see figure 2.1) we decided not to test the effect of 3mNTX on M6G or
morphine at doses < 0.2 mg/kg.
Hence, our data permit the conclusion that in contrast to the data obtained in mice
and rats on analgesia,8–13,16 our data do not suggest the presence of a unique 3mNTX-
sensitive M6G receptor in the ventilatory control system of the cat. In agreement with
our findings, in rhesus monkeys, 3mNTX was able to antagonize the antinociceptive
effects of heroin as well as morphine.39 Note, however, that our design is unable to
exclude the existence of a separate (3mNTX-insensitive) M6G binding site. It may
well that such a binding site may need to be pursued in less complex systems than the
ventilatory control system.
There are several alternative explanations for our observations. First of all, morphine
and M6G interact with distinct subpopulations of the µ-opioid receptor, which are
differentially expressed on the various neuronal substrates of the ventilatory control
system. These subpopulations may be splice variants of the µ-opioid receptor gene. In
mice, at least fifteen of such variants arising from alternative splicing have been iden-
tified.40 Another explanation could be that morphine and M6G, acting at the same
opioid receptor, may activate different G-proteins. This in turn causes differences in
signalling events and consequently divergence in behavioural responses.41 The differ-
ences in respiratory effect could also be due to differences in distribution of morphine
and M6G within the brain compartment.42 Finally, morphine and M6G may differen-
tially activate excitatory pathways within the ventilatory control system. This may be
similar to the hyperalgesic responses observed after M6G infusion but not morphine in
mice lacking the µ-opioid receptor.15,28
A final point of criticism may be that in the current study we found larger pre-drug
(i.e., baseline) values for the peripheral and central CO2 sensitivities compared to some
of our previous studies (cf. e.g., DeGoede et al.21). In both awake and anesthetized
animals and in humans the variability in ventilatory CO2 and hypoxic sensitivities is
considerable (20 to 30%),43,44 and this applies particularly to the relative contributions
of the peripheral and central chemoreptors to the total ventilatory CO2 response.
45 By
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itself the ratio peripheral/central CO2 sensitivity is insensitive to the depth of anes-
thesia.46 This does not exclude, however, that the depth of anesthesia in our present
animals may have been somewhat less because, compared to our previous studies,
we adapted premedication (reducing the ketamine dose) and the inhalational and in-
travenous anesthesia (using sevoflurane rather than halothane for maintenance and
reducing the chloralose-urethane dose). This then may have resulted in larger baseline
ventilatory CO2 sensitivities than in some of our previous studies. Other causes for the
observed differences may be biological variability related to genetic components (e.g.
the use of inbred animals in our current study). It is important to note, however, that
irrespective of the baseline parameter values, the chosen anesthetic regimen results in
a stable preparation and steady experimental conditions over several hours (over more
than six hours).25
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Naloxone reversal of buprenorphine induced respiratory depression
3.1 Introduction
Long-acting opioids are important tools in the treatment of postoperative acute pain
and chronic cancer and non–cancer pain. When selecting one of the available com-
pounds, not only must the analgesic properties be considered, but also the safety
profile of the drug. In general, opioids are well tolerated. Among the typical opioid
side effects, however, respiratory depression is of special importance because of the risk
of fatal outcome for the patient.
Buprenorphine is a potent analgesic (a hundred-fold more potent than morphine) with
µ-agonistic, opioid receptor-like 1 (ORL-1) receptor agonistic, and κ-antagonistic opi-
oid properties. In patients, buprenorphine is used for treatment of acute and chronic
pain via various administration modes, such as intravenous, transdermal, sublingual,
epidural, or spinal administration. In humans, buprenorphine behaves as a typical µ-
opioid receptor agonist, showing analgesia, euphoria, sedation, respiratory depression,
and pupillary constriction.1,2 Buprenorphine has a high affinity for opioid receptors
and it has slow receptor association and dissociation compared to other opioids.3 After
an intravenous infusion of 0.2 – 0.4 mg/70 kg, the duration of action of buprenorphine
is approximately 6 – 8 hours. Data obtained in opioid-naive volunteers indicate that
buprenorphine causes dose-dependent respiratory depression that levels off at greater
buprenorphine doses (i.e., plateau or ceiling of respiratory effect).4
Surprisingly few studies have addressed the ability to reverse the respiratory effects
of opioids in general and buprenorphine in specific. Just two studies, dating from the
1980s, as well as some anecdotal data, suggest that the respiratory depression from
buprenorphine is resistant to antagonism by naloxone.5–7 Relatively low bolus doses
of intravenous naloxone have no effect, whereas high doses (2.5 – 10 mg) causes only
partial reversal of the respiratory effects of buprenorphine. These results may be ex-
plained by the short duration of action of a bolus dose of naloxone (resulting from
a rapid elimination), combined with the high affinity of buprenorphine for µ-opioid
receptors. Consequently, a bolus dose of naloxone may be unable to displace buprenor-
phine from the opioid receptors. The buprenorphine-naloxone data contrast data on
the ability to reverse fentanyl-induced respiratory depression, which is considered rela-
tively easy. Short naloxone infusions up to 0.4 mg cause full reversal of fentanyl-induced
respiratory depression in patients during halothane-N2O anesthesia.
8
We performed a series of experiments to study the influence of naloxone on buprenorphi-
ne-induced respiratory depression. Our aim was to obtain a naloxone-dosing regimen
that would cause full reversal of buprenorphine-induced respiratory depression. Ini-
tially (study 1), we assessed the effect of 0.8 mg naloxone (or placebo) on 0.2 mg
intravenous buprenorphine-induced respiratory depression in healthy volunteers. In a
subsequent study (study 2), we explored which naloxone dose causes full reversal of
0.2 mg intravenous buprenorphine induced respiratory depression. To do so, we tested
various naloxone doses in the range from 0.5 to 7 mg in separate subjects. In another
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study (study 3), we assessed the effect of a continuous naloxone (or placebo) infusion
on 0.2 and 0.4 mg intravenous buprenorphine-induced respiratory depression.
3.2 Materials and Methods
Subjects
A total of 67 male and female subjects (age range: 20 – 30 years; weight: 54 – 93 kg)
participated in and completed the studies after approval of the protocols was obtained
from the Human Medical Ethics Committee (Commissie Medische Ethiek, Leids Uni-
versitair Medisch Centrum, Leiden, The Netherlands). We obtained oral and written
consent. All subjects were healthy and did not have a history of illicit drug use or
psychiatric illness. All women were taking oral contraceptives. Subjects were asked to
have a normal night of sleep and not to eat or drink for at least six hours before the
study. They were comfortably seated in a hospital bed for the duration of the study.
They were naive with respect to the nature of the studies but were informed regarding
the risk of participating. All subjects were students at Leiden University and received
a financial reimbursement for their participation (75 – 100 euros depending on the
study).
Apparatus
Inspired and expired gas flows were measured with a pneumotachograph (Hans Rudolph,
Myandotta, MI, USA) connected to a pressure transducer and electronically integrated
to yield a volume signal. The volume signal was calibrated with a motor-driven piston
pump (stroke volume 1,000 ml, at a frequency of 20 min−1). The pneumotachograph
was connected to a T-piece. One arm of the T-piece received a gas mixture with a
flow of 45 l·min−1 from a gas mixing system, consisting of three mass flow controllers
(Bronkhorst High Tech BV, Veenendaal, The Netherlands) with which the flow of oxy-
gen (O2), carbon dioxide (CO2), and nitrogen (N2) could be set individually at a desired
level. A personal computer provided control signals to the mass-flow controllers so that
the composition of the inspired gas mixtures could be adjusted to force end-tidal O2
and CO2 concentrations (PET,O2 and PET,CO2 , respectively) to follow a specified pattern
in time, independent of the ventilatory response (i.e., dynamic end-tidal forcing).9 In
studies 1 – 3, end-tidal partial pressure of CO2 (PET,CO2) was clamped at 53 mmHg
throughout the measurements (approximately 8 mmHg above resting values), while
end-tidal partial pressure of O2 (PET,O2) was maintained at a normoxic value of 110
mmHg. The O2 and CO2 concentrations and the arterial hemoglobin-O2 saturation
were measured with a Datex Multicap gas monitor near the mouth (Datex-Engstrom,
Helsinki, Finland) and a Masimo pulse oximeter (using a finger probe) (Masimo, Irvine,
CA, USA), respectively. The gas monitor was calibrated with gas mixtures of known
concentration delivered by a gas-mixing pump (Wösthoff, Bochum, Germany). PET,O2 ,
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PET,CO2 , inspired minute ventilation (V̇i), and O2 saturation were collected on a breath-
to-breath basis and stored on disk for further analysis.
Study Design and Data Analysis
The studies were placebo-controlled and had a double blind design. The hospital phar-
macy delivered the buprenorphine hydrochloride (Reckitt Benckiser Health-care Ltd.,
Hull, United Kingdom), naloxone hydrochloride (manufactured by the pharmacy), and
placebo (0.9% NaCl). Randomization and preparation of the syringes was performed
by a physician not involved in the study. Randomization lists were obtained from
www.randomization.com.
All buprenorphine and naloxone doses are per 70 kg. All bolus infusions were given
over 90 s. Each subject participated once in any of the studies. Values reported are
mean ± SEM, unless otherwise stated.
Study 1. Sixteen subjects participated in this study. All received 0.2 mg intravenous
buprenorphine (at t = 0) followed by 0.8 mg naloxone (in eight subjects) or placebo (in
eight subjects) at t = 120 minutes. At the following time periods, steady state venti-
lation (V̇i) was measured (measurement period 7 minutes): −10 minutes (10 minutes
before drug infusion), 15, 75, 140, 180, 240, 300, 360, 420, and 480 minutes. Analysis of
variance and post hoc t-tests were performed to detect a significant effect of naloxone
on ventilation at the P < 0.05 level.
Study 2. Twenty-four subjects participated in this study. All received 0.1 mg
buprenorphine at t = 2 minutes, followed by a continuous infusion of 0.1 mg/h for
one hour (total dose = 0.2 mg in 60 minutes). At t = 32, X mg naloxone was given,
one half as bolus and one half infused over 30 minutes. The following total naloxone
doses (X) were tested: 0, 0.5, 1, 2, 3, 4, 5, 6, and 7 mg. Each dose was tested in
two subjects, except for placebo, which was tested in eight subjects. Breathing was
measured continuously from 2 minutes before buprenorphine infusion until 90 minutes
after the start of infusion. The breath-to-breath data were averaged over one minute
periods. An ensemble average (mean of the one minute subject means) was performed
on the data of the eight subjects receiving the buprenorphine-placebo combination,
allowing the calculation of buprenorphine-placebo induced respiratory effect at various
time points. To quantify the respiratory effect of naloxone relative to placebo, we used







with z: time period ranging from t = 61 to t = 63 minutes
(−1 to +1 miute at the end of the continuous naloxone infusion)
V̇placebo(z): mean minute ventilation in the placebo group during period z
V̇naloxone(z): mean minute ventilation during period z after naloxone
V̇baseline: mean ventilation of the 2 minutes before the buprenorphine infusion
This analysis will yield a quantitative measure of reversal, with 0 indicating no reversal
(naloxone no better than placebo) and 1 indicating full reversal (response returned to
pre-buprenorphine level).
Study 3 Thirty-two subjects participated in this study.
Study 3.1 Sixteen received 0.1 mg intravenous buprenorphine at time t = 2 minutes,
followed by a continuous infusion of 0.1 mg/h for one hour (total dose = 0.2 mg in
60 minutes). At time t = 32 minutes, 2 mg naloxone (n = 8) or placebo (n = 8) was
infused, followed by a continuous infusion of 4 mg/h for two hours.
Study 3.2 Sixteen other subjects received 0.2 mg intravenous buprenorphine at time
t = 2 minutes, followed by a continuous infusion of 0.2 mg/h (total dose = 0.4 mg in
60 minutes) for one hour. At time t = 32 minutes, 3 mg naloxone (n = 8) or placebo
(n = 8) was infused, followed by a continuous infusion of 4 mg/h for two hours. The
bolus naloxone dose was 50% greater than that of study 3.1. This was based on a pilot
study in three subjects that showed the need for a greater initial dose of naloxone after
0.4 mg but not after 0.2 mg buprenorphine.
Ventilation was initially measured continuously from 2 minutes before buprenorphine
infusion until 120 minutes after the start of infusion. Subsequently measurements were
made at 30 minute intervals until t = 240 minutes, after which hourly measurements
were performed until t = 420 minutes. The breath-to-breath data were averaged over
one-minute periods. An ensemble average was performed in the naloxone and placebo
data groups. The values were compared with baseline ventilation (± its 95% confidence
interval).10 When the mean ventilation value equalled or crossed (baseline ventilation
− 1 ∗ 95% confidence interval), we somewhat arbitrarily assumed that ventilation had
returned to pre-drug baseline.
3.3 Results
All subjects completed the studies without major side-effects. The most frequent side
effects were sedation (which occurred in all subjects) and nausea (which occurred in
46 of the 67 subjects).
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Figure 3.1: Effect of placebo on 0.2
mg buprenorphine-induced respiratory
depression. Values are the mean values
± SEM (n = 8) of the 1-minute averages
of individual subjects. Diamonds rep-
resent buprenorphine infusion; squares
represent naloxone infusion.
Study 1
In the placebo group, buprenorphine decreased ventilation from 24.2 ± 1.7 l·min−1 to
13.6 ± 3.4 l·min−1 at t = 75 min; in the naloxone group, ventilation decreased from
26.5 ± 2.1 l·min−1 to 14.4 ± 1.7 l·min−1 at t = 75 (not significant, analysis of variance).
After infusion of 800 µg naloxone, ventilation at none of the measurement times differed
between placebo and naloxone groups (analysis of variance). To detect a small effect
of naloxone on ventilation unobserved in the pooled data analysis, we calculated the
difference in ventilation from t = 75 to t = 180 minutes. In the placebo group, the
change in ventilation was 0.2 ± 0.5 l·min−1, versus 2.2 ± 0.7 l·min−1 in the naloxone
group. This difference did not reach the level of significance (P = 0.08, one-tailed
Student t-test, assuming a larger response in the naloxone group).
Study 2
The mean effect of buprenorphine–placebo on minute ventilation is given in figure 3.1
and in figure 3.2 (grey area). Baseline ventilation was 24.0 ± 3.3 l·min−1 at a fixed
PET,CO2 of 52.9 ± 0.9 mmHg. Peak depression of ventilation occurred at t = 71 minutes
after the start of the buprenorphine infusion, reaching a value of 13.5 ± 1.5 l·min−1.
Relative to baseline, peak depression was 62 ± 11% of baseline, indicating a reduction
of baseline ventilation by 38%. To get an impression of the naloxone data, we plotted
representative data of two subjects given 2 and 6 mg naloxone in figure 3.2. The subject
receiving 2 mg showed full reversal back to baseline (reversal = 1). In contrast, the
subject given the higher naloxone dose showed little reversal (reversal = 0.1). In figure
3.3, we plotted the individual dose-reversal data for time frame 61 – 63 minutes. The
data show that full reversal ± 20% was obtained at doses between 2 and 4 mg naloxone
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(a) 2 mg naloxone over 30 minutes





















(b) 6 mg naloxone over 30 minutes
Figure 3.2: Individual plots of the actions of different naloxone doses on 0.2 mg buprenorphine-
induced respiratory depression. Gray field in the background is the result of the placebo group.
Diamonds represent buprenorphine infusion; squares represent naloxone infusion.
but that at higher doses, reversal gradually declined. We calculated the naloxone dose
causing 50% reversal was 0.95 ± 0.09 mg and the dose causing the return to 50%
depression was 5.20 ± 0.94 mg naloxone. Using NONMEM,11 a sigmoid Emax function
incorporating an inhibitory component was fitted to the data:
Y =
Xγ1




(1 + Xγ2 )
]
with Y : reversal
X1: dose/D1
X2: dose/D2
D1 is the naloxone dose causing 50% reversal, and D2 is the naloxone dose causing the
return to 50% depression. Values obtained are D1 = 0.95 ± 0.09 mg, D2 = 5.20 ± 0.94
mg and γ = 4.77 ± 0.22 (median ± SE). See also figure 3.3.
Study 3
Baseline ventilation averaged to 21.9 ± 2.5 l·min−1 (data from studies 3.1 and 3.2 com-
bined). The effects of both doses of buprenorphine (0.2 and 0.4 mg) were successfully
reversed by a continuous infusion of naloxone at the dose chosen by us, which was, at
least partly, based on the data from study 2.
Study 3.1. See figure 3.4a. A buprenorphine dose of 0.2 mg caused a rapid decrease
in ventilation. Before naloxone or placebo infusion (t = 32 minutes), ventilation was 84
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Naloxone dose (mg/70 kg)
D1 D2
Figure 3.3: Influence of 0 (placebo)
and 0.5 – 7.0 mg naloxone on 0.2 mg in-
travenous buprenorphine-induced res-
piratory depression. Circles are values
of individual subjects (2 subjects re-
ceived 0.5 mg naloxone, 8 subjects re-
ceived placebo). Gray field indicates
the area of full reversal ± 20%. Note
the biphasic nature of the naloxone re-
sponse.
± 3 and 79 ± 5% of baseline, respectively. In the placebo group, ventilation declined
further to a nadir of 57 ± 6% of baseline at t = 120 minutes. In the naloxone group, the
nadir was 78 ± 4% of baseline at t = 48 minutes (at the same time period, ventilation was
61 ± 5% of baseline in the placebo group). From that point on, ventilation increased to
reach baseline values (i.e., baseline ventilation − 1 ∗ 95% confidence interval) at t = 70
minutes. Ventilation did not differ from baseline during the remainder of the naloxone
infusion. After termination of the naloxone infusion (at t = 152 minutes), ventilation
decreased, but it never reached the level observed in the placebo group.
Study 3.2. See figure 3.4b. A rapid decrease in ventilation occurred after the ini-
tiation of the 0.4 mg buprenorphine infusion. Before naloxone or placebo infusion (t
= 32 minutes), ventilation was 62 ± 5% and 64 ± 5% of baseline, respectively. In the
placebo group, ventilation declined further to a nadir of 40 ± 3% of baseline at t = 150
minutes. In the naloxone group, the ventilation nadir was 61 ± 5% of baseline at t = 34
minutes (ventilation of the placebo group was 66 ± 7% at t = 34 minutes). From that
point on, ventilation increased to reach baseline values at t = 93 minutes. Ventilation
did not deviate from baseline during the remainder of the naloxone infusion. After
termination of the naloxone or placebo infusion (at t = 152 minutes), the changes in
ventilation were similar to those observed in study 3.1.
3.4 Discussion
In our studies we observed that an intravenous dose of naloxone of 0.8 mg had no ef-
fect on respiratory depression induced by the opioid analgesic buprenorphine. We next
explored the naloxone dose-response relation and observed that increasing doses of
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(a) 0.2 mg buprenorphine iv





















(b) 0.4 mg buprenorphine iv
Figure 3.4: Influence of a continuous infusion of naloxone and placebo on buprenorphine-induced
respiratory depression. Black circles represent naloxone (n = 8 per treatment); open circles represent
placebo (n = 8 per treatment). Mean ventilation data are relative to baseline ± SEM. The gray
area represents the 95% confidence interval of predrug baseline ventilation. The diamonds represent
buprenorphine infusion (t = 2 until t = 62 minutes), the squares represent naloxone infusion (t = 32
until t = 152 minutes).
naloxone caused full reversal of buprenorphine respiratory depression (2 – 4 mg nalox-
one given in 30 minutes). Further increasing the naloxone dose (5 – 7 mg), however,
caused a decline in reversal activity. The form of the dose-response relation is best
described by a bell-shape or inverse U. Taking into account these data, we designed a
naloxone infusion scheme intended to cause full reversal of the respiratory depression
from 0.2 and 0.4 mg buprenorphine. A naloxone bolus dose of 2 – 3 mg, followed by a
continuous infusion of 4 mg/h, caused full reversal within 40 – 60 minutes. Renarco-
tization did occur upon the termination of the naloxone infusion. These data indicate
that reversal of buprenorphine-induced respiratory depression is possible but depends
on the naloxone dose and its inverse U-shaped dose-response relation. That is, reversal
is possible within a specific naloxone dose window. Furthermore, because respiratory
depression from buprenorphine may outlast the effects of naloxone boluses or short
infusions, a continuous infusion of naloxone may be required to maintain reversal of
respiratory depression. Note that the design of studies 2 and 3 was such that it mimics
the clinical situation in which a possible respiratory effect from a buprenorphine trans-
dermal patch must be reversed by naloxone. A subcutaneous depot of buprenorphine
will persist upon the removal of the patch. During the existence of this depot and the
need for reversal, naloxone and buprenorphine will then be released or administered
simultaneously to the blood (as they are in studies 2 and 3).
All opioids that interact with the µ-opioid receptor system depress respiration.12 The
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extent of respiratory effect is highly variable and is related to the specific opioid, the
opioid dose, the administration mode, concurrent medication, underlying disease, pain
and the state of arousal (these two factors vary over time), genetics, and exogenous
stimulatory factors. Because the occurrence of overt and sometimes life-threatening
respiratory depression is often unpredictable, the ability to induce rapid opioid reversal
is of evident importance. In contemporary medicine, naloxone has become the drug of
choice for treatment of opioid-induced respiratory depression. Naloxone is a nonspe-
cific opioid receptor antagonist (i.e., it antagonizes the µ-, κ-, and δ-opioid receptors)
with a relatively short duration of action resulting from rapid elimination; its half-life
in plasma is approximately 30 – 45 minutes.13
There is ample evidence that buprenorphine, like other µ-opioid receptor agonists,
produces significant respiratory depression at clinical doses (figs. 3.1 and 3.4), al-
though we recently showed that buprenorphine-induced respiratory depression, unlike
other µ-opioids, shows an apparent maximum in effect (ceiling).4,14 Interestingly, only
sparse data from the literature has addressed the issue of reversal of buprenorphine
induced respiratory depression.5–7 The picture that emerges from these few studies is
that even at relatively large bolus naloxone doses, little (i.e., only partial) reversal
of the respiratory effects of buprenorphine is observed. For example, a recent short
report indicates that an incremental naloxone dose of 2.4 mg has an effect on 0.4 mg
buprenorphine-induced respiratory depression no greater than placebo in patients dur-
ing sevoflurane-N2O anesthesia.
7 An older study by Gal5 showed only partial reversal
of 0.3 mg buprenorphine with 5 and 10 mg intravenous naloxone (given as single bo-
lus). The inability to obtain full reversal in these two studies may be related to various
factors, such as anesthesia (anesthesia must be considered a serious complication when
studying opioid-induced respiratory depression due to the complex opioid-anesthetic
interaction on breathing),15,16 the lack of sensitivity of the respiratory model applied
to assess naloxone-buprenorphine interaction, the use of single naloxone doses, and
finally, the use of an overly high dose of naloxone (fig. 3.3).
The resistance to naloxone reversal is related to the high affinity of buprenorphine
for the µ-opioid receptor.1,3 This high affinity explains why relatively high doses of
naloxone (2 – 4 mg) are needed before reversal is observed. The need for a continuous
infusion in this process (upon termination of the naloxone infusion, there was a rapid
return of respiratory depression; fig. 3.4) implies the need for continuous supply of
naloxone to the opioid receptor sites in the brain involved in respiratory depression.
Otherwise, the naloxone bolus is rapidly washed out from the brain compartment and
eliminated from the body. We believe that the use of a single dose of naloxone infusion
to reverse opioid-related overdose has several disadvantages that are unrelated to the
opioid involved: renarcotization due to the short duration of action of naloxone, the
inability to titrate to effect causing the return of pain, and sympathico-excitation. An
infusion regimen aimed at a prolonged and steady state naloxone plasma concentration
may overcome these shortcomings. For example, continuous (eleven hour) naloxone
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infusion after high-dose fentanyl anesthesia caused reversal of respiratory depression
without causing renarcotization, pain, or sympathico-excitation.17
An interesting observation in studies 3.1 and 3.2 is that higher ventilation levels were
recorded after naloxone treatment than after placebo treatment at times when nalox-
one is washed out from the brain and possibly also from the body (fig. 3.4 at t = 240
minutes). This is probably due to washout from the brain compartment of buprenor-
phine which was replaced by naloxone at the µ-receptor or at nonspecific binding sites
(i.e., some buprenorphine was lost without replacement).
Naloxone doses exceeding the maximal effective dose (> 4 mg) lead to a decrease in (0.2
mg) buprenorphine reversal efficacy (fig. 3.4a). Because the number of subjects was
limited (just two subjects per naloxone dose over the dose range from 0.5 to 7 mg), we
consider this observation preliminary. Evidently, further studies are needed. In a first
attempt, we performed a set of experiments after 0.4 mg buprenorphine and applied
various naloxone doses (one dose per subject; duration of naloxone infusion 30 minutes)
and observed a similar bell-shaped dose-response relation, albeit full reversal was not
reached (A. Dahan, unpublished observation, September 2004 – January 2005). Our
unexpected observation is most probably specific to buprenorphine and its interaction
with naloxone. Buprenorphine has a long history of showing bell-shaped dose-response
curves with respect to its analgesia and side effect profile.1 Most of these observations
were made in animals. For example, rodents display a bell-shaped buprenorphine dose–
response relation in various antinociceptive assays (electrical pain, heat pain, visceral
pain, and spinal nerve ligation).18,19 In humans too, there are indications of the ex-
istence of a bell-shaped dose-response curve with respect to analgesia. For example,
two patients treated with buprenorphine (0.03 – 0.04 mg/kg) for postoperative pain
showed improved pain relief after 0.4 mg naloxone infusion, probably due to shifting
of the bell-shaped dose-analgesia curve to the right.20 A rightward-shift of the bell-
shaped buprenorphine dose-response curve after the infusion of an opioid-antagonist
(naltrexone) has been observed in rats using an electrical pain test.21 A bell-shaped
curve for buprenorphine’s analgetic effect was never observed in experimental human
studies and clinically, complete analgesia is reached with buprenorphine.
The mechanism of the bell-shaped curve remains unknown. Some argued that the form
of the curve is related to the type and intensity of (experimental) pain administered.21
Others suggested non-competitive auto-inhibition, in which there are two receptor sub-
populations, one mediating the agonistic properties at low dose, the other mediating
the antagonistic properties at high dose.3,18,19,21 Finally, Lutfy et al.22 suggest the con-
tribution of the ORL-1 receptor. They showed that buprenorphine, but not morphine,
given to mice activates ORL-1 receptors, compromising (antagonizing) analgesia from
µ-opioid receptors. The latter theory seems unplausible, however, when one takes into
account that the sparse literature that exists on the respiratory effects of stimulation of
ORL-1 receptors shows respiratory depression rather than stimulation.23 The existence
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of two µ-opioid receptor subpopulations as described above could theoretically explain
our findings with high-dose naloxone causing the antagonism of the receptors mediating
the antagonistic effects of buprenorphine. We are not aware, however, of any observa-
tion of these two receptor subpopulations in in vitro or in vivo animal studies. The
results of our studies demonstrate that the specific dose and mode of administration
of naloxone to restore breathing and to maintain it at an adequate level are complex
matters that require further study. Our data show that even after administration of
large boluses of naloxone or boluses plus brief infusions, respiratory depression induced
by buprenorphine recurred and persisted for the duration of the study (seven hours in
study 3). Additional studies are required to define the dose and the mode of admin-
istration of naloxone to restore breathing and to maintain it at an adequate level in
the clinical setting, which is complicated by acute and chronic pain, gender effects,24
high doses of opioids, long-acting opioids, and various sustained-release preparations
of opioids.
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Different time-effect profiles for naloxone
reversal of morphine and M6G-induced
respiratory depression
Eveline van Dorp, Erik Olofsen and Albert Dahan
PK/PD analysis of naloxone use in respiratory depression
4.1 Introduction
In clinical practice, opioids remain the cornerstone of pain therapy. One of their great
disadvantages however is the number of side-effects they cause, such as sedation, nau-
sea, vomiting and respiratory depression. Especially the latter is highly important,
as it can lead to coma or even death of the patient. Opioid antagonists, such as
naloxone, enable reversal of opioid-side effects. Reversal is not only dependent on the
pharmacokinetics and pharmacodynamics characteristics of naloxone itself but also on
the pharmacokinetics (PK) and pharmacodynamics (PD) of the opioid that requires
reversal.1,2 However there is limited knowledge on the complex interaction of naloxone
and the various opioids used in clinical practice. Despite the widespread clinical use of
naloxone in opioid overdose, few studies addressed naloxone reversal of opioid-induced
respiratory depression.3–7
In our laboratory, we recently modeled the interaction of buprenorphine and naloxone
regarding buprenorphine-induced respiratory depression.8 To our knowledge, there are
no other PK/PD models on reversal of opioid-induced respiratory depression. In the
current study, we performed a series of experiments with naloxone, morphine (MOR)
and morphine-6-glucuronide (M6G), investigating the effects of these opioids and sev-
eral naloxone doses on ventilation. The aim of this study was to characterize naloxone’s
reversal of respiratory depression induced by these two opioids. Taking the pharmacoki-
netic parameters from previous studies8–10 and using minute ventilation at a constant
carbon dioxide (CO2) level as an end-point for the pharmacodynamic analysis, we per-
formed a pharmacodynamic modelling study.
4.2 Methods
Subjects
A total of 56 male and female volunteers (age range: 18 – 34 years, weight range: 50
– 95 kg) participated in 2 main studies (study A and study B, for study design, see
table 4.1). They were recruited after approval of the protocol by the local Human
Ethics Committee. Oral and written consent was obtained from all subjects. Before
participation, all subjects were screened at the Pre Operative Screening Unit of the
Anesthesiology Department of the Leiden University Medical Center (LUMC). All
subjects were healthy and did not have a history of drug or alcohol abuse. All women
were taking contraceptives. On the study day itself, subjects were asked to refrain
from alcoholic beverages for at least twelve hours prior to the study, and from any food
or drink for at least eight hours prior to the study. After arrival in the laboratory,
subjects were seated comfortably in a hospital bed.
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Subgroup Study A (M6G) Study B (MOR)
1 0 µg (placebo) 0 µg (placebo)
400 µg 400 µg
2 25 µg 200 µg
100 µg
Table 4.1: Schematic overview of the study design
Apparatus
For the whole duration of the study, peripheral oxygen saturation (SpO2) of the subjects
was monitored using a fingerprobe with a Masimo Signal Extraction Pulse Oximeter
(Masimo Co., Irvine, CA, USA). Subjects breathed through a face mask (Intersurgi-
cal, Wokingham, United Kingdom). In- and expired gas flows were measured with
a pneumotachograph (Hans Rudolph, Myandotta, MI, USA) connected to a pressure
transducer and integrated to yield a volume signal. The pneumotachograph was con-
nected to a T-piece. One arm of the T-piece received a gas mixture, with a flow of 45
l·min−1, from a gas-mixing system consisting of three mass-flow controllers (Bronkhorst
High-Tech BV, Veenendaal, The Netherlands), that could be used to individually set
the flow of nitrogen (N2), oxygen (O2) and CO2 at a desired level.
A personal computer provided signal control to the mass-flow controllers so that the in-
haled gas mixtures could be adjusted to be able to force the end-expiratory levels of O2
and CO2, regardless of the ventilatory response (dynamic end-tidal forcing technique).
End-tidal O2 concentration (PET,O2), end-tidal CO2 concentration (PET,CO2), tidal vol-
ume (VT ), respiratory frequency (f), inspired minute ventilation (V̇i) and peripheral
oxygen saturation (SpO2) were collected and stored on disk for further analysis. The
in- and expired O2 and CO2 concentrations were measured with a Datex Multicap gas
monitor (Datex Engstrom, Helsinki, Finland). The software for steering the respiration
and for collecting the above mentioned parameters (ACQ and ResReg) was custom-
built locally in the LUMC.
At the start of the experiment, before drug infusion, resting values (PET,O2 , PET,CO2 , V̇i)
for the volunteers’ breathing were obtained. Next, subjects’ respiration was stimulated
by gradually increasing PET,CO2 until a inspired minute ventilation (V̇i) of between 20
and 30 l·min−1 was reached. Once steady state was accomplished, V̇i values were stored
on disk for further analysis. These values were taken as baseline values for the other
measurements. The PET,CO2 at which ventilation was increased to about 20–30 l·min
−1
(on average 7.0 kPa), was kept constant for the duration of the measurements.
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Study design
Both studies were placebo controlled and had a single blind design. Both studies had
two subgroups – so there were four subgroups (A1, A2, B1 and B2), with seven arms
in total (see Table 4.1). Initially, only the experiments in subgroups A1 and B1 were
performed. Due to the unexpected results found in those studies, we decided that more
naloxone doses would need to be studied before we could draw any firm conclusions.
Hence the need for experiments in subgroups A2 and B2. Randomization took place
within the four subgroups, but subjects were kept naive with respect to the particular
drugs they would receive in their subgroup. They were told they would either receive
morphine or M6G, followed by either a placebo or a dose of ‘antidote’.
M6G was supplied by CeNeS Ltd (Cambridge, UK). The hospital pharmacy delivered
morphine (manufactured by Teva Pharmachemie, Haarlem, The Netherlands), nalox-
one (manufactured by the pharmacy) and placebo (0.9% NaCl, manufactured by the
pharmacy). All drug doses are per 70 kg, and all doses were administered as bolus in-
jections over 90 s. Before the start of experiments, an anti-emetic drug (ondansetron,
4 mg iv) was administered to all subjects.
Study A1 Sixteen subjects participated in this study. All received a bolus dose
of 21 mg morphine-6-glucuronide (M6G) at t = 0 minutes followed by 400 µg nalox-
one (in eight subjects) or placebo (in eight subjects) at t = 55 minutes. Continuous
measurement of respiration started at t = 45 minutes and continued until t = 145 min-
utes. Subsequent measurements of steady-state ventilation (measurement period ± 7
minutes) took place at time points 180, 210 and 240 minutes.
Study B1 Sixteen subjects participated in this study. All received a bolus dose of
10.5 mg morphine at t = 0 minutes, followed by 400 µg naloxone (in eight subjects)
or placebo (in eight subjects) at t = 30 minutes. Respiration was measured constantly
from two minutes before morphine infusion until t = 90 minutes. Subsequent steady
state ventilation was measured at time points 150, 180 and 210 minutes.
Study A2 Sixteen subjects participated in this study, which was the follow-up study
to study A1. All subjects received an M6G bolus dose of 21 mg at t = 0 minutes, which
was followed by a naloxone dose at t = 55 minutes of either 25 µg (eight subjects) or 100
µg (eight subjects). Respiratory measurements were continuous from t = 45 minutes
until t = 120 minutes.
Study B2 Eight subjects participated in this study, which was the follow-up study
to study B1. In this study, subjects received a morphine bolus dose of 10.5 mg, which
was followed by a bolus dose of naloxone 200 µg at t = 30 minutes. Respiration was





Plotting and descriptive statistical analyses were conducted using the statistical pack-
age R (version 2.8).11 The breath-to-breath data, obtained from the pneumotachograph
using the ACQ and ResReg software were averaged over one minute periods. An ensem-
ble average was performed on all groups separately. We compared baseline ventilation
levels and the levels of ventilation just before administration of the antidote, within
the studies, using a one-way ANOVA.
Time of maximum reversal (i.e., time at which ventilation levels were highest), tmax, as
well as the corresponding levels of ventilation, V̇max, were computed for each individual
and averaged per group. These were considered ‘summary measures’ and compared
using a one-way ANOVA within the studies.12 Then tmaxand V̇max were compared be-
tween the two studies using a Student t-test. In all comparisons, a p < 0.05 was
considered significant.
Pharmacokinetic Models
Because in this study no blood samples were taken, we assume that morphine, M6G
and naloxone concentrations can be described by earlier established pharmacokinetic
models.8–10
Pharmacodynamic Model
The differential equations describing morphine or M6G (M) and naloxone (N) molecules
binding receptors (R) are13
d[MR]
dt
= kon,M · [M ] · [R] − koff,M · [MR] (4.1)
d[NR]
dt
= kon,N · [N ] · [R] − koff,N · [NR].
If koff,N is large we may assume kon,N ·[N ]·[R]−koff,N[NR] = 0, or [NR] = [N ]·[R]/C50,N,
with C50,N = koff,N/kon,N. Furthermore, with [RT ] = [R] + [RM ] + [RN ], and the




1 + [N ]/C50,N
· (1 − [MR]) . (4.2)
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Naloxone dose (µg) 0 25 100 400
Age (yr) (range) 24.0 (18–34) 21.5 (18–27) 20.9 (18–24) 22.3 (19–34)
Weight (kg) 70.6 ± 11.8 65.9 ± 6.6 70.4 ± 9.5 65.6 ± 9.03
Height (cm) 176 ± 8.8 171 ± 9.2 180 ± 8.0 173 ± 5.5
Sex (m:f) 3:5 3:5 4:4 5:3
Baseline ventilation 28.65 ± 4.16 25.36 ± 2.6 23.71 ± 1.5 23.79 ± 4.7
Table 4.2: Baseline characteristics for study A; group means with standard deviations





1 + ([N ]/C50,N)
γ · (1 − [MR]) . (4.3)
The delay between drug concentration in the blood and at the receptor site(s) was
characterized by parameters t1/2,ke0 for each drug.
Finally, ventilation V̇ was assumed to be dependent on [MR] according to
V̇ = V̇0 · (1 − [MR]). (4.4)
where V̇0 is the baseline (pre-drug) value. Because [MR] was normalized, 0 < [MR] < 1
and 0 < V̇ < V̇0.
Statistical Analysis
The pharmacodynamic data were analyzed using NONMEM VI14. Model parameters
were assumed to be log-normally distributed across the population, except the Hill
parameter γ, which was assumed to lie between 0 and 20 via the inverse logit trans-
formation, to avoid extremely large values of γ causing numerical problems. Residual
error was assumed to be additive with variance σ2.
4.3 Results
All 56 subjects completed the study without major side-effects. Their baseline char-
acteristics, divided by subgroup, are shown in table 4.2 and 4.3. Minor side-effects
that were reported included ‘heavy feeling’ (exclusively in study A), nausea, but no
vomiting (in both studies) and sedation (exclusively in study B). All symptoms were
mild and did not need further treatment.
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Naloxone dose (µg) 0 200 400
Age (yr) (range) 21.9 (19–24) 23.0 (19–26) 22.4 (20–27)
Weight (kg) 67.8 ± 17.4 71.4 ± 9.1 67.6 ± 16.6
Height (cm) 174 ± 10.8 175 ± 7.9 179 ± 8.9
Sex (m:f) 2:6 3:5 4:4
Baseline ventilation 22.19 ± 6.7 25.28 ± 1.8 20.60 ± 2.3
Table 4.3: Baseline characteristics for study B; group means with standard deviations
Descriptive analysis
Baseline ventilation averages can be found in tables 4.2 and 4.3. Because there were
significant differences between the M6G subgroups (the placebo subgroup differed sig-
nificantly from the 100 and 400 groups, one-way ANOVA p=0.026), we did all further
descriptive analyses using the relative ventilation values (i.e., absolute ventilation val-
ues divided by the baseline ventilation). This led to the graphs seen in figures 4.1 and
4.2, where the mean relative ventilation values are shown.
We observed that after administration of the opioids, ventilation levels fell quickly to
about 65% of baseline ventilation (M6G per subgroup: 67.7, 65.8, 66.3 and 65.4 %;
MOR per subgroup: 69.1, 67.1 and 70.4 %) just before administration of the antidote.
Comparison of these values for both studies separately showed no significant differences
(study A, one-way ANOVA: p= 0.635 and study B, Student t-test: p=0.358). Com-
parison of both studies (using a pooled average for study A and study B: 65.4 ± 1.7%
and 70.4 ± 2.3 % respectively) showed no significant differences either (Student t-test,
p=0.075), suggesting that at the doses used in this study, morphine and M6G cause
the same amount of CO2-driven respiratory depression. A comparison of tmax-values
shows a mean tmax of 44.39 ± 2.73 minutes for the M6G groups (pooled average) and a
mean tmax of 13.33 ± 1.2 minutes, a significant difference of 31 minutes (p < 0.001). So
maximum reversal is reached far later in the M6G group than in the morphine groups.
PK/PD analysis
Initially, all 56 subjects were included in the PK/PD analysis. However, three outliers
were identified. In study A (M6G), ID 25 was an outlier with respect to C50,N. The
data from this subject were not discarded, but C50,N was fixed to 10. ID 31 from study
A was also an outlier and therefore γ was fixed to 20. In study B, ID 5 was an outlier
and those data were discarded.
Morphine, M6G and naloxone pharmacokinetic parameters for a similar group of sub-
jects have been published earlier.8–10 For the present re-analyis, weight was introduced
as a covariate. Dose was proportional to weight. For the pharmacodynamic param-
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(b) 25 µg naloxone


















(c) 100 µg naloxone


















(d) 400 µg naloxone
Figure 4.1: Actions of different naloxone doses in study A (M6G). Figure (a) represents the absolute
group average ± SEM for the placebo group. Figures (b), (c) and (d) show separate group means



















































(b) 200 µg naloxone


















(c) 400 µg naloxone
Figure 4.2: Actions of different naloxone doses in study B (morphine). Figure (a) represents the absolute group average ± SEM for the placebo
group. Figures (b) and (c) show separate group means ± SEM, relative to baseline ventilation. Grey field in the background is the relative mean
of the placebo group
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Θ SE ω2 SE
t1/2,ke0,M6G (h) 2.72 0.422 0.187 0.0770
kon,M (nM
−1·min−1) 0.0371 0.00825 0.421 0.130
koff,M (min
−1) 0.0327 0.00455 0.0459 0.0456
t1/2,ke0,N (min) 5.42 0.532 – –
C50,N (nM) 0.484 0.102 0.233 0.0622
V̇0 (l·min
−1) 25.3 0.790 0.0180 0.00613
γ 7.42 1.19 1.75 0.869
σ2 (l·min−1) 1.83 0.195
Table 4.4: Pharmacody-
namic parameters for study
A (M6G). Θ is the popu-
lation parameter, ω2 is the
variance of Θ across the pop-
ulation in the log domain.
ω2 was not estimable for the
t1/2,ke0 .
Θ SE ω2 SE
t1/2,ke0,M (h) 1.24 0.172 0.160 0.0727
kon,M (nM
−1·min−1) 0.853 0.112 0.192 0.0672
koff,M (min
−1) 0.138 0.0148 0.112 0.0514
t1/2,ke0,N 11.2 2.66 – –
C50,N (nM) 1.84 0.181 0.141 0.0463
V̇0,200 (l·min
−1) 26.5 1.10 0.0144 0.00342
V̇0,400 (l·min
−1) 21.5 1.03 0.0144 0.00342
γ 4.18 0.718 0.938 0.432
σ2 (l·min−1) 2.18 0.347
Table 4.5: Pharmacody-
namic parameters for study
B (morphine). Θ is the
population parameter, ω2 is
the variance of Θ across the
population in the log domain.
The V̇0 differed significantly
between the two groups, and
is therefore shown as two
separate parameters. The
t1/2,ke0 for the 400 µg group
was not estimable, so only
the t1/2,ke0 shown only applies
to the 200 µg. ω2 was not
estimable for the t1/2,ke0 .
eters, see tables 4.4 and 4.5. In figures 4.3 and 4.4 representative plots of data from
individual subjects are shown, together with their model fit.
4.4 Discussion
At the doses chosen, morphine and M6G cause ventilatory depression of similar mag-
nitude with a depression of baseline ventilation of about 35%. The respiratory effects
of both opioids can be reversed, but the characteristics of reversal differed. Our data
support the clinical observation that reversal of morphine-induced respiratory depres-
sion sets in rapidly and lasts about 30 minutes. After that, opioid effect returns and
respiratory depression becomes apparent again. For M6G, a different picture emerges
from our data: time to maximum reversal is relatively slow (45 minutes for M6G versus
13 minutes for morphine), but reversal does last longer.
From the PK/PD modelling, two main observations were made. First, the C50 for
naloxone differs between the M6G and morphine groups. This implies that the po-



























(a) ID 12: 25 µg naloxone


















(b) ID 6: 100 µg naloxone

















(c) ID 20: 400 µg naloxone
Figure 4.3: Representative examples of individual fits for each subgroup in study A (M6G). R2 for these fits is 0.83, 0.91 and 0.88 respectively,
R2 for all fits ranges from 0.49 to 0.91, median R2 = 0.74.
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(a) ID 20: 200 µg naloxone





















(b) ID 18: 400 µg naloxone
Figure 4.4: Representative examples of individual fits for each subgroup in study B (morphine). R2
for these fits is 0.89 and 0.88 respectively, R2 for all fits ranges from 0.38 to 0.90, median R2 = 0.78.
tory effects are reversed at a lower dose of naloxone. A higher potency of naloxone
in M6G-induced respiratory depression may be due to a specific kind of interaction
between these two drugs at the receptor level, in which one of the two drugs increases
the affinity of the other drug at the µ-opioid receptor. This has been described in 1988
by Abbott and Palmour15, who showed that M6G increased binding of naloxone to
µ-opioid receptors at rat brain membrane preparations. They also state that morphine
does not have this effect. Furthermore, it could be that M6G changes the state of the
G-protein associated with the µ-opioid receptor, thus altering the signalling cascade
within the cell. Circumstantial evidence for this is that M6G causes hyperalgesia in
specific pain tests, which could be caused by ‘flipping’ the G-protein to a different
state.16 Further, it could be that M6G limits the efflux of naloxone from the brain
compartment, and thus increasing the apparent potency of naloxone. Finally, it may
well be that morphine and M6G act at a different opioid-receptor (see Chapter 2 and
references therein), each with a different naloxone affinity.
A second observation in our PK/PD analysis is that a ‘simple’ competitive interaction
model is not sufficient to describe our data: the introduction of a Hill factor (γ 6= 1)
is needed to adequately describe the data. The high γ found for both morphine and
M6G would suggest that naloxone reversal of opioid-induced respiratory depression is
subject to a threshold phenomenon: if naloxone brain concentration exceeds a certain
level, reversal sets in, and if it would fall below this level, reversal wanes. This could
be in concordance with the naloxone efflux limitation mentioned above.
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The combination of a γ and a difference in C50 could also be explained differently.
Shafer et al. postulate in a recent article that if an antagonist would act at several
places in the signalling cascade, this would increase the apparent potency (lower C50)
and steepness (γ) parameters.17 If naloxone would not only act at the µ-opioid recep-
tor, but also at different places in the signalling cascade (a second binding place on the
µ-opioid receptor itself, an influence on the G-protein state, a direct influence on the
K+ channels of the neuron, or even a separate receptor), the C50 and the introduction
of the γ could be explained.
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Naloxone and M6G induced hyperalgesia
5.1 Introduction
In contemporary clinical medicine, µ-opioids such as morphine are the first choice for
treating severe acute and chronic pain.1 However, opioid use is associated with several
unwanted side-effects, including a paradoxical increase in pain sensitivity. This opioid-
induced hyperalgesia (OIH) has been reported in pre-clinical studies with rodents and
humans and described in the clinical literature.1–4 Although it is widely postulated
that activating opioid receptors or opioid analgesia are critical initial prerequisites for
OIH,5–9 contrary results have been recently reported. For example, infusing the µ-
opioids morphine and oxymorphone evoked hyperalgesic responses within 48 hours in
opioid receptor triple “knock-out” (TrKO) mice completely devoid of opioid recep-
tors.10 Hyperalgesia during continuous morphine infusion is also observed in outbred
CD-1 mice implanted with pellets containing naltrexone (NTX), a general opioid re-
ceptor antagonist.11,12 N-methyl-D-aspartate (NMDA) receptor antagonists such as
MK-801 reverse morphine hyperalgesia.11,12 Since NMDA antagonists also potentiate
opioid analgesia, they might attenuate hyperalgesia indirectly, by increasing the latent
opioid analgesia obfuscated by the concurrent increased nociception. However, this
possibility is precluded by the demonstration that MK-801 reverses morphine hyper-
algesia in NTX-pelleted mice.11,12
In humans, morphine undergoes hepatic glucuronidation to more water-soluble com-
pounds, facilitating their renal elimination.13 One of these metabolites, morphine-6-
glucuronide (M6G), displays affinity at µ-opioid receptors equal to that of morphine,
and is a potent opioid analgesic.13,14 However, data from some studies suggest that
acute M6G doses can cause hyperalgesia. In the first two, a single acute M6G injec-
tion reduced tail-withdrawal latencies by up to 40% in mice lacking exons 1 and/or
2 of the µ-opioid receptor.15,16 In a third study, low M6G doses (10 and 20 mg/70
kg) progressively increased the time to rescue analgesic medication in patients after
orthopedic surgery, while a higher dose (30 mg/70 kg) caused a subsequent decrease in
the time to rescue medication, which may be considered a manifestation of hyperalge-
sia.17 Finally, we recently demonstrated in an open label study that a single injection
of M6G increased pain ratings in healthy volunteers that underwent a cutaneous heat
pain assay.18 Since M6G hyperalgesia was not the specific aim of these studies, sev-
eral questions remain. Specifically, it is not known whether M6G causes hyperalgesia
independently of opioid receptor activity, or whether NMDA receptors contribute to
this effect. Furthermore, since only acute doses of M6G were injected in these studies,
it is not known what effect longer M6G delivery protocols might have on nocicep-
tion. These questions can not be adressed by simply extrapolating from studies with
morphine, as morphine metabolism in mice does not yield M6G. Furthermore, mor-
phine conjugation in rodents and humans also yields morphine-3-glucuronide (M3G), a
pronociceptive metabolite thought to underlie morphine hyperalgesia.10–12,19,20 If both
morphine metabolites are indeed pronociceptive, it would not be possible to distinguish
between their hyperalgesic effects in human subjects treated with morphine.
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Here, we addressed these issues by assaying nociceptive sensitivity in mice and human
volunteers injected with an acute M6G dose. The contribution of opioid receptors
to M6G hyperalgesia was assessed by treating subjects concurrently with an opioid
receptor antagonist. Additional evidence was obtained by testing TrKO mice devoid
of any opioid receptor type under identical conditions. The long-term consequences of
M6G infusion on nociception was also assessed by assaying nociception daily in mice
subject to six days of continuous M6G infusion. For both acute and chronic M6G
treatment conditions, the ability of the non-competitive NMDA receptor antagonist
MK-801 to reverse hyperalgesia in mice was tested. Since MK-801 can potentiate
latent M6G analgesia concurrent with hyperalgesia, mice in this treatment condition
were also simultaneously treated with NTX.
5.2 Methods
Animal Studies
Subjects and nociceptive assay All procedures were approved by the College of
Staten Island/City University of New York Institutional Animal Care and Use Com-
mittee and conform to guidelines of the International Association for the Study of Pain.
Adult male CD-1 mice were purchased (Charles Rivers, Kingston, NY, USA) whereas
TrKO mice (gift of John Pintar, Robert Wood Johnson Medical School, Piscataway,
NJ, USA) were derived by cross-breeding mice singly deficient in the genes coding for
µ, κ and δ receptors using standard homologous recombination techniques.21,22 Ac-
cordingly, B6129F1 mice were bred and served as TrKO controls. The combinatorial
mice are devoid of brain or spinal cord [3H]-naloxone receptor labelling, indicating the
complete absence of any µ, κ and δ opioid receptor subtype, and lack gross behavioural
or anatomical alterations.21,22 Mice were maintained on a 12:12 hour light/dark cycle
in a climate-controlled room with free access to food and tapwater. Each subject was
used once and for all studies n = 6. The tail-withdrawal test of D’Amour and Smith was
chosen for its stability in the context of repeated testing.10–12,23 Tails of the mice were
immersed in water maintained at 47.3 ± 0.2 ◦C, which elicits pre-opioid baseline (BL)
latencies between 9 and 11 s, minimizing possible floor effects during hyperalgesia. La-
tency withdrawal was recorded twice at 30 s intervals and averaged. A cutoff latency of
30 s was used to prevent tissue damage. Nociception was tested near mid-photophase
to reduce circadian effects on the test-results.24
Drug delivery M6G (NIDA Drug Supply Program, Bethesda, MD, USA) and MK-
801 (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in saline and injected sub-
cutaneously. Whereas acute doses were injected in a volume of 10 ml/kg, continuous
infusion was achieved using osmotic pumps (Alzet Model 2001, Alza, Mountain View,
CA, USA).10–12 The pumps were implanted under O2/isoflurane anesthesia through a
small dorsal midline incision. Osmotic pumps afford continuous opioid infusions and
control for hyperalgesia associated with withdrawal in opioid-dependent subjects that
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potentially confounds experiments where chronic opioid treatment is accomplished via
repeated acute injections.25 Pellets containing 30 mg of the general opioid receptor an-
tagonist naltrexone or a placebo formulation (NIDA Drug Supply Program, Bethesda,
MD, USA) were wrapped in nylon mesh and subcutaneously implanted in the nape
of the neck twenty-four hours prior to M6G delivery by acute injection or continuous
infusion. In rats, 30 mg NTX pellets substantially elevate NTX plasma levels one hour
after implant, and sustain pharmacologically active levels of NTX such that there is
a greater than fifty-fold rightward shift of the morphine analgesia dose-response curve
eight days later.26 In mice, NTX pellets completely abolished the analgesic effect of an
acute 10 mg/kg morphine injection starting twenty-four hours after implant (coinciding
here with start of M6G infusion) and for a minimum of seven additional days.11
Study design Nociception was assayed before (i.e., baseline or BL) and at 30 minute
intervals for 120 minutes after an acute M6G (10 mg/kg) or saline injection in CD-1
mice implanted with NTX or placebo pellets. TrKO mice and their B6129F1 con-
trols were subject to the identical acute injection protocol with the exception that
they were not implanted with pellets of any kind. The effect of continuous M6G (1.6
mg·kg−1·24h−1) or saline infusion on nociception was tested for six consecutive infusion
days in separate groups of CD-1 mice implanted with NTX or placebo pellets. In these
groups, withdrawal latencies were measured before the start of infusion (BL) and on
each subsequent day. Finally, the ability of an acute MK-801 (0.05 mg/kg) dose to
reverse M6G hyperalgesia was tested in separate groups of CD-1 mice implanted with
NTX pellets. The MK-801 dose chosen for study does not increase tail-withdrawal
latencies in naive or saline-infused mice.10,12,27 For the acute M6G condition, mice
were first injected with MK-801 and then an acute M6G dose (10 mg/kg) 30 minutes
later. Nociception was assayed immediately before the M6G injection (BL) and at
30 minute intervals for the next 2 hours. Mice subject to continuous M6G infusion
(1.6 mg·kg−1·24h−1) were assayed for nociception prior to infusion (BL) and on Day
4 (t = 0), at which time all mice were hyperalgesic in agreement with the continuous
infusion study above. Immediately after assaying nociception on Day 4, MK-801 was
injected and nociception was reassessed at 30 minute intervals for 2 hours. Control mice
in both acute and chronic M6G conditions were injected with saline vehicle instead of
MK-801.
Data analysis Depending on experimental design, withdrawal latencies were anal-
ysed using a two- or three- way analysis of variance followed by Fisher’s LSD (protected
t-test) for post-hoc comparisons. P-values < 0.05 were considered significant. All ani-
mal values are reported as group mean ± SEM withdrawal latencies.
Human Studies
Subjects Forty human volunteers (aged 18-39 years; twenty women/twenty men;
BMI < 30) were recruited to participate in the studies after approval of the protocols
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was obtained from the Leiden University Medical Center Human Ethics Committee.
All candidates underwent a physical examination and only healthy subjects without a
history of illicit drug use or psychiatric illness were allowed in the study. All subjects
were advised not to eat or drink for at least eight hours prior to the start of the study.
The subjects were randomly allocated to one of four treatment groups:
1. In 10 subjects 0.4 mg/kg iv M6G was injected during a background iv infusion
of naloxone (bolus 0.04 mg/kg, followed by 0.04 l·min−1·h−1)
2. In 10 subjects 0.4 mg/kg iv M6G was injected during a background iv infusion
of normal saline
3. In 10 subjects iv placebo (0.9% NaCl) was injected during a background iv infu-
sion of naloxone (bolus 0.04 mg/kg, followed by 0.04 l·min−1·h−1)
4. In 10 subjects iv placebo (0.9% NaCl) was injected during a background iv infu-
sion of normal saline
The naloxone/saline infusion started 30 minutes prior to the M6G/placebo infusion
and lasted for 2.5 hours (end of study). Thermal pain measurements were performed
just prior to the naloxone bolus infusion (t = − 30 minutes), just prior to the M6G
bolus infusion (t = 0 min) and next at 10 minute intervals (first hour of the study) and
20 minute intervals (second hour of the study).
Drugs M6G was donated by CeNeS Ltd (Cambridge, United Kingdom), naloxone
was purchased from Orpha-Devel GmbH (Pukersdorf, Austria). Placebo/saline (NaCl
0.9%) was manufactured by the local pharmacy. Randomization (using lists obtained
from www.randomization.com) and preparation of the syringes were performed by a
physician not involved in the study. M6G bolus was infused over 90 s, naloxone bolus
over 120 s.
Pain Measurements Heat pain was induced using the TSA-II device running the
WinTSA 5.32 software package (Medoc Ltd, Ramat Yishai, Israel).28 Using a 3 cm2
Peltier element or thermode, the skin of the volar side of the left forearm was stimulated
with a gradually increasing stimulus (0.5 ◦C/s). Baseline temperature was set at 32
◦C. Subjects were asked to verbally rate their pain on a scale from 0 (no pain) to
10 (worst pain imaginable), i.e., a numerical rating scale (NRS). After the subjects
were familiarized with the device and NRS scoring, the NRS to three heat stimuli was
assessed with the following peak temperatures: 47, 48 and 49 ◦C. The lowest stimulus
causing a NRS between 5 and 7 was used in the remainder of the study. The test data
were discarded. Next baseline values were obtained in triplicate (the averaged value
was used in the data analysis). In order to prevent frequent stimulation of just one
part of the skin, we divided the volar side of the test arm into six zones and moved
thermode from zone to zone (1 to 6 and back) between subsequent stimuli.28
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Data Analysis To assess the effect of iv drug infusion over time an analysis of vari-
ance using a repeated measures design was performed. To assess the effect of naloxone
versus saline treatment, we calculated time adjusted area-under-the ∆ effect curves
(AUEC, where ∆ effect is the effect above the pre-M6G/placebo value) and tested the
significance of differences by Student t-test (a separate analysis was performed in M6G
treated and placebo treated subjects). P-values < 0.05 were considered significant.
Values reported are mean ± SEM.
5.3 Results
Animal Studies
Nociception after acute M6G injection As illustrated in figure 5.1a, an acute 10
mg/kg M6G dose increased withdrawal latencies for at least 120 minutes in CD-1 mice
implanted with placebo pellets (P < 0.01). In contrast, this potent analgesia was not
evident in NTX pelleted controls. Instead, M6G increased nociception, thereby signifi-
cantly reducing tail withdrawal latencies from baseline (10.5 ± 0.4 s) at t = 90 minutes
(8.3 ± 0.2 s, P < 0.05) and t = 120 minutes (7.8 ± 0.3 s, P < 0.01). Similar results were
obtained when assaying nociception after acute M6G (10 mg/kg) injection in TrKO
mice and their B6129F1 controls (figure 5.1b). Whereas M6G caused maximal analge-
sia for a minimum of 120 minutes in control mice, it caused only significant hyperalgesia
during the same time period in TrKO mice completely lacking opioid receptors. For all
strains in both acute M6G conditions, saline injection in either placebo- or naltrexone-
pelleted mice did not alter withdrawal latencies from baseline values (data not shown
for clarity). This finding is consistent with previous reports.10–12,27,29
Nociception during continuous M6G infusion Continuous subcutaneous M6G
infusion (1.6 mg·kg−1·24h−1) produced no detectable analgesia in either placebo or
NTX pelleted mice. Instead, increased nociception was evident starting on infusion
Day 1, and continued until the end of study on Day 6 (Figures 5.2a and 5.2b). The
magnitude of this hyperalgesia was at a maximum on infusion Day 4, where baseline
latencies were reduced from 8.9 ± 0.2 s to 6.1 ± 0.3 s in placebo pelleted mice (P < 0.01;
figure 5.2a), and from 9.1 ± 0.2 s to 5.3 ± 0.2 s in mice implanted with NTX pellets
(P < 0.01; figure 5.2b). The magnitude of the latency reductions in placebo and NTX
pelleted mice were highly similar throughout the six test days, and significantly differed
from each other on Day 3 only. As in previous studies,10–12 withdrawal latencies did
not differ from baseline values during saline infusion in either placebo- or NTX-pelleted
mice (data not shown for clarity).
Effect of NMDA receptor blockade on M6G hyperalgesia Mice injected with
saline 30 minutes prior to an acute M6G (10 mg/kg) dose displayed significant re-
ductions in withdrawal latencies relative to baseline at t = 60 minutes (figure 5.3a).
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(b) TrKO and control
Figure 5.1: Two-hour time course of tail-withdrawal latencies following a single sc injection of
10 mg/kg morphine-6-glucuronide (M6G, given at t = 0) in mice. Data are mean ± SEM latencies
obtained prior to M6G infusion (0) and at 30 minute intervals during M6G infusion.
A. CD-1 mice implanted with placebo (open circles, n = 6) or naltrexone pellets (closed circles, n =
11) 24 hours prior to M6G injection. Data are mean ± SEM latencies obtained prior to M6G infusion
(0) and at 30 minute intervals during M6G infusion. Significant treatment, time and time treatment
effects were observed (all P < 0.001). Post-hoc comparisons: * P < 0.01 and ** P < 0.05 versus BL
(pre-M6G baseline).
B. Opioid triple knockout mice (TrKO: open circles, n = 7) and the B6129F1 control animals (closed
circles, n = 7). Significant treatment, time and time x treatment effects were observed (all P < 0.001).
Post-hoc comparisons: * P < 0.01 and ** P < 0.05 versus BL (pre-M6G baseline).
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(b) M6G and naltrexone
Figure 5.2: Six-day time course of tail-withdrawal latencies in CD1 mice during the continuous
subcutaneous infusion of M6G (infusion rate = 1.6 mg/kg per 24 h). Data are mean ± SEM latencies,
obtained prior to M6G infusion (BL) and at daily intervals during M6G infusion. Significant main
effects were observed for time (P < 0.0001) and time x treatment (P <0.01), but not for treatment
(P >0.05). Post-hoc comparisons: * P < 0.01 versus BL.
in subjects injected with MK-801 (0.05 mg/kg) instead of saline. Figure 5.3b illus-
trates pain responses in mice subject to continuous M6G infusion (infusion rate 1.6
mg·kg−1·24h−1). Whereas latencies were significantly increased relative to pre-infusion
BL values (9.6 ± 0.5 s) at t = 0 on Day 4 (7.2 ± 0.2 s, P < 0.01), a subsequent MK-801
(0.05 mg/kg) injection reversed this hyperalgesia, increasing withdrawal latencies to
the BL values obtained prior to the start of the M6G infusion within 30 minutes (9.9
± 0.1 s, P < 0.01 versus t = 0 values). Latencies remained elevated for at least 120
minutes after MK-801 injection. In contrast, injecting saline instead of MK-801 did not
alter latencies in a separate group of M6G-infused control mice displaying significant
hyperalgesia of approximately equal magnitude on Day 4.
Human Studies
The naloxone infusion scheme was designed to achieve a steady state concentration
> 10 ng/ml, which is assumed to cause full reversal of µ, κ and δ opioid receptors,
even when dealing with high affinity opioids.30,31 Subjects receiving M6G (0.4 mg/kg
iv) showed increased pain responses irrespective of the naloxone or saline background
infusion (figures 5.4A and 5.4C), significantly different from baseline (t = 0) from t = 30
to t = 120 minutes. NRS increased from 6.2 ± 0.2 (t = 0) to a maximum of 7.2 ± 0.2 at t
= 60 minutes in the naloxone group (P < 0.05), and from 6.0 ± 0.2 (t = 0) to a maximum
of 7.1 ± 0.3 at t = 100 minutes in the placebo group (P < 0.05). AUECs did not differ
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(b) MK-801 and continuous M6G infusion
Figure 5.3: Effect of an acute injection of MK-801 on tail withdrawal latencies in CD-1 mice given
an acute injection of 10 mg/kg M6G (A) or in CD-1 mice on the fourth day of a continuous infusion
of M6G (B). All mice are NTX pelleted. Data are mean ± SEM values. Post-hoc comparisons: * P
< 0.01 and ** P < 0.05 versus BL (pre-M6G baseline). x P < 0.01 versus t = 0.
A: Following MK-801 (open circles, n=6) or saline (closed circles, n = 6) injection, the pain response
to an acute injection of 10 mg/kg M6G was tested for two hours. Significant treatment, time and
time treatment effects were observed (all P < 0.01).
B: During the continuous sc infusion of M6G, 0.05 mg/kg sc MK-801 (open circles, n = 6) or saline
(closed circles, n = 6) was injected just after the latency measurement on day 4 (pre-MK-801 latencies
here shown at t = 0). Significant treatment, time and time treatment effects were observed (all P <
0.01).
receiving placebo/saline (figure 5.4B) and placebo/naloxone (figure 5.4D) showed no
systematic changes in NRS. AUECs did not differ between the two placebo groups:
0.10 ± 0.15 mA (saline) versus −0.16 ± 0.13 mA (naloxone).
5.4 Discussion
One of the main findings in mice is that acute M6G injection increases pain sensitivity
in mice subject to opioid receptor blockade by naltrexone and in TrKO mice lacking
all opioid receptors. In addition, we observed that continuous M6G infusion causes
long-lasting (six day minimum) increases in pain sensitivity that start within 24 hours,
irrespective of the presence or absence of opioid receptor blockade with naltrexone.
The final finding in mice was that NMDA receptor blockade with MK-801 respectively
blocks or reverses the increased pain sensitivity induced by the acute injection or con-
tinuous infusion of M6G in NTX pelleted mice. In humans, we observed that a single
intravenous injection of M6G increased pain sensitivity for at least six hours (figure
5.4). Furthermore, consistent with our above findings in mice, the increased pain sen-
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sitivity observed after M6G injection in humans exposed to a noxious thermal stimulus
persisted during the simultaneous continuous infusion of naloxone.
An array of mechanisms is proposed to underlie opioid-induced hyperalgesia. For ex-
ample, opioids can directly activate a subpopulation of opioid receptors coupled to an
excitatory (i.e., Gs) effector mechanism, distinct from those (i.e., Gi/o-coupled) me-
diating analgesia, to prolong the action potential of dorsal root ganglion neurons.7
Others provide evidence consistent with the hypothesis that hyperalgesia is an adap-
tive response. In such a scenario, increased nociception is a consequence of an opioid
receptor-mediated opponent-process acting as a foil to opioid analgesia.7 A series of
studies also describe a system-wide mechanism integrating spinopetal projections from
the rostro-ventral medulla with spinal alterations that modulate primary afferent ac-
tivity.6 Despite their diversity, these accounts unanimously characterize hyperalgesia
as a consequence of opioid receptor activity or analgesia. However, here we report
that M6G hyperalgesia is manifest in mice and humans treated concurrently with high
enough doses of opioid antagonist so that opioid receptors (and analgesia) are com-
pletely blocked. Furthermore, we observed M6G hyperalgesia in TrKO mice where
opioid receptors are altogether absent. Importantly, there were no changes in nocicep-
tion in NTX or placebo-pelleted mice injected with saline, indicating that hyperalgesia
was a consequence of M6G exposure. Therefore, the present data indicate that M6G
causes hyperalgesia in mice and humans that, like morphine and oxymorphone hyper-
algesia in mice,10–12 is independent of concurrent opioid receptor activity or analgesia.
We have previously demonstrated that morphine and oxymorphone can cause hyper-
algesia via mechanisms unrelated to their opioid activity.10–12 To this list of clinically
relevant opioids we now include M6G, which is currently undergoing phase III clinical
trials.17,32 Thus, despite the fact that all three opioids preferentially act via the µ-
opioid receptor, their hyperalgesic liability is unrelated to their common opioid receptor
pharmacodynamics. We, and others, have previously speculated that OIH might result
from the conjugation of the parent opioid compound at the 3’-postion into pronocicep-
tive glucoronide metabolites.10–12,19,20 M3G, for example, the most abundant morphine
metabolite,33 has no detectable affinity at any opioid receptor subtype or analgesic ef-
fect,29,34–37 and systemic M3G doses can decrease tail-withdrawal responses in mice and
evoke agitation to even innocuous touch in rats that is not diminished by naloxone.4,29
M3G accumulation has also long been thought to underlie morphine hyperalgesia in
humans. Oxymorphone metabolism also yields oxymorphone-3-glucuronide, a metabo-
lite similar to M3G.38 With regards to M6G, itself a morphine metabolite, we are not
aware of any reports showing that M6G metabolism directly yields any neuroexcita-
tory or pronociceptive fragments. However, M6G injection increases M3G levels in
mice within sixty minutes, an effect attributable to the metabolism of morphine that
is generated from the enterohepatic circulation of M6G.39 Here, the onset of hyperal-
gesia after an acute M6G injection in NTX-pelleted mice was generally similar (t = 90




















































































Figure 5.4: Influence of 0.4 mg/kg M6G and placebo on experimental heat pain responses in human
volunteers during background exposure to saline (A and B, grey diamonds) and background exposure
to naloxone (C and D, grey squares). During saline (A) and naloxone (C) background infusion
M6G causes an immediate and persistent hyperalgesic response. In contrast, placebo produces no
consistency in response independent of the background infusion (B and D). Values are the mean ±
SEM. Significant main effects: (A) M6G/saline, P < 0.01; (C) M6G/naloxone, P < 0.001. Post-hoc
comparisons: * P < 0.05 versus t = 0.
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receptor antagonist MK-801 blocked or reversed hyperalgesia elicited by an acute injec-
tion or the continuous infusion of M6G, respectively. Although the M3G binding site
and mechanism of action is not known, the neuroexcitatory effects of M3G are thought
to involve NMDA receptor activity and NMDA receptor antagonists dose-dependently
reduce M3G symptoms, including enhanced nociception.34,40,41 However, based on data
from a previous study,39 it is unlikely that the acute M6G dose injected here would re-
sult in physiologically relevant concentrations of M3G to cross the blood-brain barrier,
although such an accumulation may be possible during continuous M6G infusion. In
humans, M3G levels remain undetected after an acute M6G injection, and acute M3G
injection in humans was without effect on nociception.36,37,42 Therefore, at this time,
we can only speculate as to whether M3G might contribute to M6G hyperalgesia. Ac-
cordingly, any such contribution may be dependent on the duration of M6G exposure
(i.e., acute injection or continuous infusion) and the species studied. These issues will
comprise the specific aims of future studies.
Regardless of the mechanism underlying morphine, oxymorphone and M6G hyperal-
gesia, and whether all three opioids cause hyperalgesia via common mechanisms, the
present data suggests that hyperalgesia after M6G has a more rapid onset and is more
robust. For example, we previously showed that an acute subcutaneous morphine or
oxymorphone injection in TrKO mice at doses identical to M6G doses administered
here (10 mg/kg) did not reduce tail-withdrawal latencies even after 120 minutes.10 In
contrast, here we report that opioid receptor blockade significantly reduced withdrawal
latencies within 90 minutes in CD-1 mice. Furthermore, whereas hyperalgesia caused
by continuous morphine infusion in both placebo- and NTX-pelleted CD-1 mice is de-
layed until Day 4,11,12 significant hyperalgesia is already manifest 24 hours after the
start of continuous M6G infusion, regardless of the concurrent pellet treatment. These
data suggest that M6G activates pronociceptive mechanisms more rapidly or effica-
ciously than either morphine or oxymorphone. This might explain why relatively high
doses of M6G are required to elicit an adequate analgesic response in experimental
and clinical studies with humans.13,32,42 That is, the ability of M6G to rapidly evoke
significant hyperalgesia in a variety of delivery circumstances may offset any concur-
rent analgesic effect. At higher M6G doses, there is presumably a greater increase in
the analgesic effect relative to hyperalgesia, and analgesia is manifest. This assump-
tion can be directly tested by assaying thermal pain responses in humans subject to
morphine. We are embarking on just such a study, and our preliminary data indeed
show that a single intravenous injection of morphine does not cause pain ratings on our
thermal assay to increase in a manner similar to that observed here with M6G (Van
Dorp 2006, unpublished observation), suggesting that M6G hyperalgesia to heat pain
is more readily manifest than hyperalgesia wrought by morphine.
Multiple studies show the ability of NMDA receptor antagonists to reverse OIH,6,11,12,26
and here the non-competitive NMDA receptor antagonist MK-801 was effective in
blocking or reversing hyperalgesia after acute injection and continuous infusion of M6G,
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respectively. The present data thus demonstrate that M6G hyperalgesia in mice is de-
pendent on NMDA receptor activity. There is currently no definitive explanation on
how NMDA receptor antagonists reverse opioid hyperalgesia. A possible direct interac-
tion of NMDA antagonists with opioid receptors (cf., Sarton et al. 43 ) would be a moot
point since we show here in NTX-pelleted mice that M6G hyperalgesia is unrelated to
opioid receptor activity. For identical reasons, it can also not be the case that MK-801
reversed M6G hyperalgesia only indirectly, by potentiating latent M6G opioid anal-
gesia concurrent with hyperalgesia. Kilpatrick and Smith reported that while M6G
was inactive at two binding sites within the NMDA receptor, suggesting the absence
of a direct blockade of M6G activity at these sites, it is not yet possible to rule out
M6G activity at other sites within the receptor complex.14 It has also been suggested
that NMDA antagonists block or reverse opioid hyperalgesia by antagonizing NMDA
receptors localized to central primary afferent terminals that cause spinal sensitization
and increased nociceptive input.6 To this we add the possible contribution of NMDA
receptors at loci up- or down-stream from the site where pronociceptive mechanisms
are activated in response to M6G administration. Further studies are needed to ad-
dress these possibilities.
Although just 5 to 10% of morphine is metabolized to M6G, M6G plasma concentra-
tions increase rapidly after acute morphine administration and reach relatively high
values after chronic treatment, particularly when renal function is compromized. Thus,
M6G may not only make an important contribution to morphine analgesia but, as we
demonstrate here, to hyperalgesia as well. This potential role for M6G as causative
factor of morphine hyperalgesia requires further study. M6G is also currently in phase
III clinical trials as an opioid analgesic and is thought to possess a pharmacological
profile that imbues it with certain advantages relative to other opioids in the manage-
ment of pain. The addition of another clinically effective opioid is certainly a welcomed
addition to the opioid pharmacopeia. However, despite whatever advantages M6G may
afford for the treatment of pain, the present results suggest that the absence of hyper-
algesia is not one of them.
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Naloxone treatment in opioid addiction
6.1 Introduction
Although opium has been in use for many centuries, opioid addiction only became a
major global problem since the mid 1800s.1 In the US alone, almost 3 million people
aged over 12 years have used heroin, of which 326,000 people received treatment for
heroin abuse.2 In Europe, 1.2 – 2.1 million people are known to be problematic drug
users, most of whom use opioids (often in combination with other (illicit) drugs).3,4 Of
these drug abusers, 450,000 people receive treatment for their addiction. Besides the
fact that addicts are more likely to develop mental illness or exhibit criminal behaviour,
they are also at risk for fatal overdose and various infectious diseases, such as hepatitis
B and C and HIV. The number of drug-related deaths in EU member states is estimated
to be in the range of 7000 – 9000 per year.4 Opioid addiction can, therefore, be viewed
as a major medical and social problem.
The recent advancements in the understanding of the neurobiology underlying addiction-
related behaviour have contributed to the recognition that opioid addiction is a serious
complication of chronic opioid intake in some individuals (note that patients receiving
opioids for chronic pain do not necessarily develop addiction). Nowadays, addiction is
considered a chronic disease of the brain rather than a mental illness carrying a social
stigma.5 New perspectives in the neurobiology of opioid addiction offer unique oppor-
tunities for the development of novel treatment strategies. However, as the disease has
a multifactorial etiology, treatment must always be multidisciplinal, combining both
pharmacologic and psychologic interventions. The pharmacologic interventions are ei-
ther aimed at detoxification and permanent abstinence from illicit drugs, or at the
attenuation of (often protracted) withdrawal symptoms using opioid replacement ther-
apy. Although sometimes complete abstinence is achieved, often lifelong substitution
is the chosen therapy mode. Methadone substitution therapy is the main cornerstone
in the treatment of opioid addiction, although in some countries a clear shift is seen in
treatment approach with buprenorphine rather than methadone being the first-choice
substitution therapeutic.6
This short review discusses some of the pharmacologic strategies of opioid addiction
treatment with special focus on the benefits and risks of the non-selective opioid-
receptor antagonist, naloxone.
6.2 Addiction and the µ-opioid receptor
Opioids exert their effects through specific opioid receptors. The existence of three
subtypes (µ, κ and δ) is accepted. The µ-opioid receptor subtype, especially, mediates
the positive reinforcing effects of heroin and other illicit opioids. This receptor subtype
is, therefore, considered crucial in the development of opioid addiction.7 Dedicated
in vivo studies have shown that mice lacking the µ-opioid receptor (exon 2 µ-opioid
receptor gene knockout mice) display less self-administration of morphine and reduced
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conditioned place preference,8 underlining the importance of the µ-opioid receptor in
the development of opioid addiction.
Drugs of abuse, in general, overstimulate those neural systems in the brain that are
normally reserved for the response to natural reward systems. In this respect, the
mesolimbic dopamine system, as well as the nucleus accumbens, is considered a rele-
vant part of the ventral tegmental area in the midbrain.9,10 Acute administration of
drugs of abuse induces the release of high levels of dopamine in the nucleus accum-
bens, resulting in an increased feeling of reward. Opioids cause dopamine release by
inhibiting the γ-aminobutyric acid-ergic inhibition of dopamine release in the ventral
tegmental area, a typical part of the midbrain with a high density of µ-opioid recep-
tors.11 Overstimulation of dopamine results in stronger deregulations of the natural
reward pathways (sensitization and tolerance) and learning processes in the brain (re-
inforcement).8
Abrupt abstinence from opioids or the administration of µ-opioid receptor antago-
nists in opioid-dependent persons will produce the opioid withdrawal syndrome. Signs
and symptoms of this syndrome include negative moods, irritability, muscular and ab-
dominal pains, gastrointestinal complaints (nausea, diarrhea), sweating, lacrimation,
malaise and insomnia.12 Symptoms usually start 6 – 12 hours after the last dose of a
short-acting opioid and 36 – 48 hours after the last dose of a long-acting opioid, such as
methadone. The duration of the syndrome is variable. Some studies report a duration
of no more than 7 – 14 days, whereas others also describe a more prolonged withdrawal
syndrome lasting from several weeks to a few months. Although the syndrome is not
life-threatening, many patients experience difficulties completing this initial phase of
the therapy.13
6.3 Pharmacologic treatment strategies in opioid
addiction
Treatment of opioid addiction should primarily be aimed at the reduction of illicit drug
use (next to stabilizing the social functioning of the patient and improving his or her
quality of life). This can be done by either gaining control of the patients drug use
by drug replacement therapy or by withdrawing the patient from all opioids (detox-
ification). It is, however, insufficient to regard complete withdrawal as the ultimate
therapy; addiction is a chronic disease (reflected in long-term changes in the brain) and
should, therefore, be treated as such. Nowadays, most patients receive maintenance
therapy consisting of µ-opioid receptor agonists or a combination of µ-opioid receptor
agonists and antagonists.
Potent and long-acting opioid agonists with low-intrinsic efficacy are considered good
candidates for opioid replacement therapy. Examples of such opioids are methadone
and buprenorphine. Methadone is a full agonist at the µ-opioid receptor, buprenor-
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phine a partial µ-opioid receptor agonist. This characteristic makes buprenorphine
an attractive alternative for methadone, because low-efficacy agonists are associated
with a lower abuse potential compared to relatively higher efficacy agonists such as
methadone. Furthermore, the partial agonist, buprenorphine, has a better safety pro-
file than full µ-opioid receptor agonists, indicating that it can be more easily titrated
to the desired effect even at high doses.14 In addition, its unique slow receptor associ-
ation/dissociation characteristic at the µ-opioid receptor contributes to the extended
duration of action following single-dose administration.15
Opioid antagonists, such as naloxone and naltrexone, reverse and prevent opioid ef-
fects by blocking the µ-opioid receptor. As discussed in section 6.2, µ-opioid receptor
blockade causes the occurrence of acute withdrawal symptoms in opioid-dependent
individuals. µ-opioid receptor antagonists are widely used in rapid and ultra-rapid
detoxification to facilitate the transition from dependence to abstinence. Antagonists
can also be used to prevent relapse, as µ-opioid receptor occupancy by opioid antago-
nists results in a decreased effectiveness of administered opioids. This diminishes the
reinforcing effects of heroin and potentially the association between opioid use and
conditioned stimuli.12
6.4 Pharmacology of naloxone
For many years, the development of non-addictive opioids, with the beneficial analgesic
action of morphine but devoid of any addictive properties, has been considered an im-
portant objective. During the twentieth century, various morphine-like substances were
synthesized and tested for their non-addictive properties. Nalorphine, a derivative of
morphine, was shown to reverse most of morphine’s typical effects at a relatively low
dose (while inducing analgesia at a high dose). In addition, nalorphine precipitates the
abstinence syndrome in opioid addicts. Although nalorphine showed promising block-
ing properties, the dysphoric effect of this opioid discouraged its widespread clinical
use.16 Additional dedicated structure-activity studies led to the discovery of naloxone.
Naloxone, an allyl derivative of noroxymorphone, was first synthesized in 1960. The
development of naloxone was encouraged by the need for a real opioid antagonist (in
contrast to the partial agonist, nalorphine) devoid of any agonistic activity at the var-
ious opioid receptors.17 Naloxone is a non-selective opioid antagonist at the µ-, δ- and
κ-opioid receptors. Naloxone competitively inhibits the pharmacologic effects of opi-
oids and, in line with the classical receptor theory, produces a parallel right shift in the
dose-response curves of opioids.18 When administered to opioid-dependent patients,
naloxone induces a severe withdrawal syndrome, as µ-opioid receptor-bound heroin is
displaced by naloxone.
Naloxone appears to be readily absorbed after oral administration, but its low bioavail-
ability renders naloxone less suitable for this administration route. Following oral ad-
ministration, naloxone undergoes extensive hepatic metabolism, indicating high first-
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pass effect (>95%). In the liver, naloxone is primarily metabolized into the inactive
conjugate naloxone-3-glucuronide. In addition to glucuronidation, naloxone is also me-
tabolized by N-dealkylation and 6-oxo group reduction (note that these metabolism
pathways represent only minor fraction of total metabolism). Approximately 30% of
the unchanged naloxone dose is excreted in the urine within six hours following in-
travenous administration; the rest of the dose is recovered as conjugated naloxone
metabolites in the urine.19
In healthy volunteers, the elimination half-life of naloxone in plasma is approximately
30 minutes. Although the elimination half-life is not expected to differ among opioid
naive and opioid dependent patients, differences in naloxone distribution in the body
may exist. For instance, Handal et al. suggest in their review that there may be
differences in pharmacokinetics between opioid-dependent and non-dependent persons,
reporting a difference in initial plasma concentration of 30%.20
Naloxone is readily transported across the blood-brain barrier and, therefore, has a fast
onset of action in reversing opioid effects.19 However, the ability of naloxone to reverse
opioid effects in vivo is mainly determined by the pharmacologic characteristics of the
interacting opioid agonist (i.e., the opioid that requires antagonism). For example,
the onset of reversal of morphine-induced respiratory depression by naloxone can be
established within a time frame of one to two minutes. On the other hand, for an opioid
with slow µ-opioid receptor association/dissociation kinetics, such as buprenorphine,
the interaction with naloxone is rather complex. Not higher doses of naloxone per se,
but a different mode of naloxone administration (i.e., continuous infusion) is indicated
to reverse buprenorphine-induced respiratory depression.14,15
Because naloxone is devoid of agonistic activity at the µ-opioid receptor, it is regarded
as a safe drug to use. This notion persists despite earlier clinical experiences show-
ing that naloxone use may (under certain specific circumstances) cause serious and
possibly life-threatening side effects, such as pulmonary edema, cardiac arrhythmias,
hypertension and cardiac arrest.21–23 It is important to note that all of the patients
described in these reports were postoperative patients experiencing (severe) pain and
stress. In a more recent prospective study24 in comatose patients due to opioid over-
dose, 453 patients were treated with naloxone. Six patients suffered from severe com-
plications (asystole, pulmonary edema and epileptic seizures), corresponding to 1.3%
of the treated population. However, the exact relationship between naloxone treatment
and the occurrence of the severe complications was not clear. The possibility that these
complications were related to the initial hit (i.e., the opioid overdose) could not be ex-
cluded. The primary reason for the development of cardio-respiratory complications
after naloxone therapy is the sudden release of central catecholamines.24 Especially
when naloxone is administered shortly after the occurrence of opioid-induced vasodila-
tion (this may occur just minutes after the opioid is administered via the intravenous
route and is visible as a sudden drop in blood pressure) or the patient is sympa-
thetically unstable (due to pain or stress), high-dose naloxone and/or rapidly infused
naloxone (i.e., not titrated) can cause catecholamine-mediated vasoconstriction. This
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then may cause cardiac arrhythmias and a fluid shift from the systemic circulation
to the pulmonary vascular bed, resulting in pulmonary edema.21 Proper monitoring
of patients receiving naloxone is therefore mandatory, especially of patients that just
recently received an opioid dose via the intravenous route or sympathetically unstable
patients. Studies in animals and healthy volunteers confirm the safety of naloxone use
in patients25,26 even at higher doses up to 10 mg,27 or following constant exposure to
intermediate-to-high concentrations of naloxone during one to two hours.28 Taking into
account the fact that there are only few reports in the literature on naloxone-related
complications (as well as taking into account their own experience), the authors con-
sider naloxone a relatively safe drug with little chance of complications.
As an alternative to naloxone, a second µ-opioid-receptor antagonist, naltrexone, was
synthesized with more favourable pharmacokinetic properties than naloxone. Although
naltrexone has a relatively low bioavailability (up to 60%), it is two to three times
more potent than naloxone.16 It undergoes extensive hepatic metabolism, but because
its metabolite, 6-β-naltrexol, is also highly active, oral administration can be effective.
Elimination half-life is approximately 4 hours, with a far longer half-life (up to 13
hours) reported for the active metabolite. Effectively, a 50 mg dose of naltrexone
will block the pharmacologic effects of a 25 mg heroin dose for up to 24 hours.29
It is employed in rapid and ultra-rapid detoxification and in abstinence maintenance
therapy.30 When compared with methadone maintenance therapy, naltrexone is the
less favourable option, as the lack of agonistic effects reduces compliance.29 However, if
retention of patients is high enough (for example with highly motivated patients or with
patients that cannot be included in a methadone maintenance program), naltrexone
maintenance therapy is an effective way of treating opioid addiction.31
6.5 Naloxone in the treatment of opioid addiction
Naloxone use in treatment of opioid overdose
The most common use of naloxone is for the treatment of opioid overdose. Heroin
overdose is one of the leading causes of death among opioid-dependent patients and
non-fatal overdoses are also highly prevalent among these patients.4 Overdose often
occurs after a drug-free period and is related to a reduction of tolerance and hence a
relatively increased opioid potency. Naloxone is effective in the treatment of opioid-
overdose and opioid-induced coma in hospital practice. Note, however, that it is vital
to take into account the specific opioid that is responsible for causing the overdose.
Most opioids used by addicts have relatively long half-lifes (of a few hours), whereas
naloxone has a half-life of only 30 minutes. As a consequence, respiratory depression,
caused by long-acting opioids (methadone, heroin, morphine), returns after the effect of
naloxone has worn off.17,32 It is, therefore, necessary to adequately dose and monitor the
patient.33 The initial naloxone bolus dose required to reverse opioid overdose should be
determined clinically, starting from 0.4 mg given as a slow bolus injection, continuing
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until the patient improves. If, after an injection of 4 – 10 mg naloxone, the patient shows
no sign of recovery, the cause of the respiratory depression is most likely not opioid-
related. After initial recovery, patients should be started on a continuous intravenous
naloxone infusion and closely monitored for signs of deteriorating clinical status for at
least 24 hours.
It is important to note that the patient may enter an acute withdrawal syndrome after
administration of naloxone, with consequent nausea and vomiting. The airway must,
therefore, be guarded at all times. Another symptom of acute withdrawal may be pa-
tient violence,34 and adequate preparation for this situation (in the form of restraints)
is needed. All this taken into account, naloxone remains the first drug of choice in
suspected opioid overdose in the hospital setting.
Because an overdose often occurs outside the hospital setting (i.e., at home or on the
streets), naloxone may not be readily available and it is therefore difficult to treat the
patient timely. Both healthcare professionals and opioid addicts themselves regarded
the idea of so-called ‘take-home naloxone’ a good strategy in the prevention of fatal
opioid overdose.35–37 Several pilot studies investigated this intervention strategy and
although the sample sizes in the studies were small, results were promising, with 90 –
100% of naloxone administrations preventing death from heroin overdose.38–40
In the United Kingdom (June 2005), naloxone was added to the list of drugs that ‘may
be administered by anyone for the purpose of saving life in an emergency’ (that is,
everyone is allowed to administer naloxone to an individual with a suspected opioid
overdose).41 It is important to educate both the patient and his or her caretakers
(not necessarily healthcare professionals) in the use of naloxone in case of a suspected
overdose. The caretakers should learn how to recognize an overdose, how to perform
mouth-to-mouth resuscitation and how to administer naloxone (either subcutaneously,
intramuscularly or intravenously).42 In addition, they should be made aware of the
necessity of always alerting emergency medical services and to provide the monitoring
and further treatment needed in case of an overdose. Often, fear of the police and
subsequent criminalisation will halt the bystanders (usually fellow addicts) in calling
an ambulance — one more reason for distributing take-home naloxone among addicts,
thus providing necessary first aid to their peers.38 Providing the family, caretakers and
friends of opioid-addicted patients are well instructed in the use of naloxone, take-home
naloxone could be a helpful strategy in combating fatal heroin overdose.
Naloxone in detoxification and maintenance
The conventional way of detoxification is treating the patients with tapering doses of
opioid agonists (methadone or buprenorphine) and/or with clonidine or lofexidine (α2-
adrenergic-receptor agonists that can relieve the symptoms of withdrawal). The pro-
tracted nature of these techniques, however, leads to a high number of initial dropouts
(dropout rates in the literature are in the range of 30 – 90%31,43). This was one of the
major reasons for the development of new withdrawal strategies, which take less time
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Naloxone use Side effects
Opioid overdose Acute withdrawal syndrome
Detofixication Recurrence of respiratory depression
Maintenance (combined with buprenorphine) Cardiac arrhythmias
Pulmonary edema
Table 6.1: Use and side effects of naloxone in opioid-dependent individuals.
and may be more comfortable to the patient. Rapid or ultrarapid detoxification under
anesthesia or heavy sedation is one such therapy. It consists of the intravenous admin-
istration of an opioid antagonist (usually naloxone). The effect of the ensuing acute
withdrawal syndrome (lasting 4 – 6 hours) is either treated (or masked) with general
anesthesia or heavy sedation (using benzodiazepines), both combined with clonidine
and β-adrenergic-receptor blockers (to prevent tachycardia). After this initial phase,
patients are introduced on an oral dosing of naltrexone as maintenance therapy, with
additional psychologic counselling as support. The effectiveness of this approach has
recently been called into question, as there is little evidence of its superiority above
‘ordinary’ opioid maintenance treatment and it appears to have a higher risk of adverse
events. In recent years, a few randomized clinical trials were conducted investigating
rapid detoxification.44,45 All concluded that rapid opioid detoxification had no proven
benefits over buprenorphine/clonidine detoxification. As the risk associated with this
therapy (e.g., the risk of anesthesia or sedation) is much greater than in the other
treatment groups and the costs are significantly higher, it is generally agreed that this
form of treatment should not be pursued any further.46
Naloxone can also be used to speed up clonidine or lofexidine-assisted opioid detoxifica-
tion (i.e., rapid detoxification with naloxone/clonidine). These α2-adrenergic agonists
alleviate withdrawal symptoms in detoxifying patients, and have proven to be as effec-
tive as tapering methadone doses in the treatment of opiate dependence.47 The addition
of an opioid antagonist, such as naloxone, to this form of detoxification therapy leads
to a more intense, but less prolonged, withdrawal syndrome. The exact implications
for long-term treatment in the form of antagonist maintenance are not yet clear.
In the past, naloxone has been used as an oral abstinence maintenance agent, but its
low oral bioavailability and (very) short duration of its action make it unsuitable for this
purpose.48 However, it can be used as test medication before administering naltrexone
to possibly dependent patients. For example, if intravenous naloxone causes no or
little withdrawal symptoms in these patients, it is safe to administer the more potent
and long-lasting naltrexone in an oral formulation.49 Furthermore, it may be used
as a diagnostic tool in discriminating between opioid-dependent and non-dependent
patients (e.g., occasional abusers or patients behaving like addicts, but ailing from
another disorder such as diabetes).
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Naloxone in combination with buprenorphine
In 2002, sublingual buprenorphine (SubutexTM, Reckitt Benckiser) and the combina-
tion of buprenorphine and naloxone (for sublingual use only, SubuxoneTM, Reckitt
Benckiser) was approved by the FDA for use in opioid addiction treatment. Because
buprenorphine alone, as a (partial) µ-opioid receptor agonist, is subject to abuse, the
combination treatment was intended to minimize the abuse and misuse of the com-
pound.50 As this form of therapy gains in popularity, the use of buprenorphine com-
bined with naloxone needs further consideration. When Subuxone is administered sub-
lingually some opioid withdrawal symptoms are only seen in those individuals who are
heavily dependent on heroin and/or recently took heroin. Most likely, the bioavailabil-
ity of naloxone after sublingual administration is too low to cause severe and protracted
withdrawal symptoms.
However, when a sublingual dose of Suboxone is administered intravenously, all ad-
dicts will experience an immediate opioid withdrawal syndrome.51 On the basis of the
pharmacologic properties of buprenorphine, partial agonism and high affinity at the
µ-opioid receptor, one would expect competitive displacement of heroin by buprenor-
phine rather than by naloxone. Surprisingly, however, there is ample evidence that
withdrawal symptoms in this particular population (opioid-dependent patients) are
caused by naloxone.51,52 This may be related to the fact that several structures in
the brain, and more specifically the opioid-receptor system, are subject to changes
following chronic exposure to opioids,5,9 thereby significantly altering the interaction
of buprenorphine with the µ-opioid receptor. One possibility is that chronic exposure
to opioids changes the behaviour of intravenous buprenorphine from a partial agonist
to a full agonist at the µ-opioid receptor with lesser affinity for the receptor than ob-
served in opioid-naive volunteers. Further studies are needed to elucidate this matter.
Several studies concluded that buprenorphine/naloxone was a good alternative for ei-
ther methadone or buprenorphine maintenance therapy.52–55 Not much is known about
whether or not the addition of naloxone truly prevents the misuse of the combination.
Evidence is only circumstantial, as it is difficult to monitor the amount of misuse.56,57
6.6 Summary and conclusions
Naloxone competitively inhibits the pharmacologic effects of exogenously administered
opioids and, in line with the classical receptor theory, produces a parallel right shift
in the dose-response curves of opioids. Naloxone is readily transported across the
blood-brain barrier and, therefore, has a fast onset of action in reversing opioid effects.
Its duration of action is limited due to its short elimination half-life of 30 minutes.
The ability of naloxone to reverse opioid effects in vivo is mainly determined by the
pharmacologic characteristics of the interacting opioid agonist (i.e., the opioid that
requires antagonism).
88
Naloxone treatment in opioid addiction
The most common use of naloxone is for the treatment of opioid overdose both in a
hospital and out-patient setting. The safety of naloxone in the treatment of opioid
overdose is well established in patients and healthy volunteers over a wide dose range
(0.4 – 10 mg). There is a special role for intravenous naloxone in rapid detoxification, in
which naloxone is combined with the α2-agonist, clonidine, and β-adrenergic-receptor-
blocking agents to treat withdrawal symptoms. The effectiveness of this approach
has recently been called into question as there is little evidence of its superiority above
‘ordinary’ opioid maintenance treatment and it appears to have a higher risk of adverse
events. Finally, naloxone is used in combination with buprenorphine maintenance
therapy. Addition of naloxone minimizes the abuse and misuse of buprenorphine and
the buprenorphine/naloxone combination is considered a good alternative for either
methadone or buprenorphine maintenance therapy (see also table 6.1).
Although naloxone is relatively safe to use, there are some apparent risks and disad-
vantages associated with its use. Naloxone induces an acute withdrawal syndrome in
opioid-dependent persons. Due to its short half-life, its effect may wear off prema-
turely when used for treatment of opioid-induced respiratory depression. High-dose
or rapidly infused naloxone administered to a patient who is overdosed with an opioid
given for the treatment of acute pain may cause catecholamine release and consequently
pulmonary edema and cardiac arrhythmias.
6.7 Expert opinion
The non-selective opioid-receptor antagonist, naloxone, is widely used in clinical prac-
tice. Anesthesiologists use naloxone for reversal of postoperative respiratory depression
induced by potent opioid analgesics, such as fentanyl, sufentail and morphine. Sim-
ilarly, naloxone may be used to treat opioid overdose in opioid-dependent patients.
There are some subtle differences in use between the two patient groups, most impor-
tantly there are differences in dosing. In postoperative patients, the initial intravenous
dose is 40 – 80 µg, which can be increased to desired effect using 40 – 80 µg titration
boluses. When respiration has returned to the desired level, an equivalent naloxone
dose is administered via the intramuscular route. Reversal is often rapid and the in-
tramuscular depot ensures that reversal lasts for 30 to 45 minutes, a time frame which
is often sufficient to overcome the respiratory problems. In opioid dependent patients,
the initial dose is 0.4 mg. Depending on the clinical status of the patient, slow titra-
tion with doses up to 10 mg of naloxone may be applied. Note, however, that for
both patient groups the mode and dose of naloxone administration is dependent on
the pharmacological properties of the opioid that induced the overdose. For long act-
ing potent opioids, such as methadone and buprenorphine, a continuous infusion of
naloxone rather than multiple bolus injections is indicated.
An interesting new development that deserves support is the use of naloxone outside the
hospital setting by non-medically trained people, so called ‘take-home naloxone’. Some
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caution is needed though. Acute withdrawal may occur with vomiting, hypertension,
tachycardia and delirium. These require acute treatment to prevent further damage
(such as aspiration). Training of family and friends of opioid addicts who receive ‘take-
home naloxone’ should therefore not be restricted to instructions how to administer
naloxone in case of a heroin overdose but also be aimed at the acute treatment of the
patient. Often the required measures are very simple: put the patient on one side,
remove the vomit and get professional help.
There is some scarce data on the deleterious effects of naloxone on the cardiovascular
system. The data is relatively old (1970s) with little new data added since. The data
indicate that rapid infusion and high dose naloxone may be dangerous to one specific
type of patient: the patient who was treated for acute and severe pain with an opioid.
When overdosed and the patient is treated with high dose naloxone (or naloxone is given
too rapidly) the abrupt exposure to the underlying problem (pain, stress, sympathetic
excitation) may cause a sudden release of catecholamines with consequently pulmonary
edema and cardiac arrhythmias. Although there is an absence in recent reports on the
cardiovascular side-effects of naloxone, which we relate to the improved care that we
give to our patients (for example by careful titration of naloxone), we still recommend
that the use of naloxone is performed during adequate cardio-respiratory monitoring.
This is especially important for the patient using ‘take-home naloxone’. He or she
should immediately be transported to the hospital and monitored for at least 12 hours
after being treated with naloxone for near-fatal respiratory depression.
In conclusion, taking into account all relevant data, current opinion is that naloxone
is a safe drug to use.
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Opioids still form the gold standard in severe pain therapy, despite their many side-
effects. One of the most important side-effects of opioid therapy is respiratory depres-
sion, a condition which is easily treatable using opioid antagonists. One such antagonist
is naloxone, a short acting opioid antagonist which has high affinity for the the µ-opioid
receptor, but with lower affinity for the κ- and δ- opioid receptors. In Chapters 2, 3
and 4, we investigated the use of naloxone in respiratory depression that was caused
by morphine, morphine-6-glucuronide (M6G) and buprenorphine.
In Chapter 2, we investigated the possible existence of a separate opioid receptor for
M6G by using a derivative of naloxone, 3-methoxy-naltrexone (3mNTX). We compared
morphine and M6G’s respiratory effects in the anesthetized cat, using the dynamic end-
tidal forcing (DEF) technique. Using the DEF technique, we can distinguish between
carbon dioxide (CO2) sensitivity of the peripheral and the central chemoreflex loops
(Gp and Gc, respectively) which are parameters in a two compartmental model for the
relationship between CO2 and ventilation. We conducted three separate studies. In
study 1, we assessed the effect of morphine, 3mNTX and M6G successively, on the
ventilatory response to CO2. In study 2 we assessed the effect of M6G, 3mNTX and
morphine successively. Study 3 assessed the effect of 3mNTX alone on the ventilatory
response to CO2. With these studies, we showed that both M6G and morphine shifted
the ventilatory CO2 responses to higher end-tidal CO2 levels. Morphine had a pref-
erential depressant effect within the central chemoreflex loop. In contrast, M6G had
a preferential depressant effect within the peripheral chemoreflex loop. Irrespective of
the opioid, 3mNTX caused full reversal of, and prevented respiratory depression. The
conclusions that could be drawn from these are twofold. We found that in anesthetized
cats, the µ-opioids morphine and M6G induce respiratory depression at different sites
within the ventilatory control system. Another conclusion drawn from this study is
that it is unlikely that a 3mNTX sensitive receptor is the cause of the differential
respiratory behaviour of morphine and M6G, as 3mNTX caused full reversal of the
respiratory depressant effects of both opioids.
For Chapter 3, we obtained data from an extensive group of healthy volunteers (n=67)
on buprenorphine’s respiratory effects and the reversal of those effects using naloxone.
The rationale behind these studies was the worldwide belief that buprenorphine’s res-
piratory effects are supposedly hard to reverse. We combined data from three separate
studies in this Chapter. In all studies, respiration was measured against a constant,
increased end-tidal CO2-level. In the first study, we investigated the effect of an in-
travenous bolus dose of 0.8 mg naloxone on 0.2 mg buprenorphine-induced respiratory
depression versus the effects of placebo. As this turned out to be insufficient to cause
reversal of the respiratory effects, we decided to test a dose range of naloxone (0.5 – 7
mg), given in a 30 minute infusion. Using the information from this study, the third
step was to test the effect of a combination of a bolus dose of naloxone and a longer




A bolus dose of naloxone turned out to be ineffective for the reversal of respiratory
depression from buprenorphine, as was observed in study 1. From study 2, we found
out that in the dose range between 2 – 4 mg, naloxone was able to cause full reversal
of respiratory depression. A higher dose (above 5 mg) caused a decline in reversal
activity. In the third study, we saw that it is possible to reverse both 0.2 and 0.4 mg
buprenorphine’s respiratory effects by using a combination of a bolus dose (2 – 3 mg)
and a subsequent continuous infusion of naloxone of 4 mg/h. The main conclusions
from this study were that reversal of buprenorphine’s respiratory effect is possible, but
that it depends on doses of both naloxone and buprenorphine. There seems to be
an inverse U-shaped curve for naloxone reversal of buprenorphine’s effects (see figure
3.3), meaning that a higher naloxone dose does not neccesarily cause more reversal of
respiratory depression. Next to that, the respiratory effects may outlast short lasting
infusions of naloxone, so it is important to use a continuous infusion of naloxone for
the reversal of buprenorphine induced respiratory depression.
In Chapter 4, we modelled the effects of naloxone on M6G- and morphine-induced
respiratory depression. We conducted a study in 56 healthy volunteers. First we com-
pared the effects of 400 µg naloxone and placebo on the respiratory effects of morphine
and M6G. Next, we investigated the effects of different naloxone doses (200 µg in the
morphine group, 25 and 100 µg in the M6G group) in both opioids. All studies were
performed under constant end-tidal CO2 pressures. We found that morphine’s effects
were quickly reversed and that this reversal was shortlasted, whilst in the M6G group,
the time to maximum effect was longer (45 minutes versus 13 minutes in the mor-
phine group), and the reversal lasted longer (up to 90 minutes). We fitted the data
to a PK/PD model, from which we were able to conclude two things. The first was
that a Hill factor (γ) needed to be introduced to our model for an appropriate fit and
the second was that there were differences in naloxone C50 in the morphine and M6G
studies. This means that naloxone has a different potency in M6G and morphine (less
naloxone is needed to reverse M6G induced respiratory depression than in morphine
induced respiratory depression). The conclusion from these studies is that morphine’s
and M6G’s effects are differently reversed by naloxone. We can still only speculate as to
how these differences are caused, but most likely is that naloxone does not only act at
the µ-opioid receptor itself, but also at a different site of action in the signalling cascade.
Reversal of respiratory depression is not the only application of naloxone, however.
Chapters 5 and 6 elaborate on different uses of naloxone, i.e., in hyperalgesia (Chapter
5) and in opioid addiction (Chapter 6).
Opioid induced hyperalgesia has recently gained the interest of researchers. It is prob-
ably caused by activation of the NMDA-receptor, which in turn could be caused by µ-
opioid receptor-activation. In Chapter 5 we tested this hypothesis specifically for M6G
in mice (outbred CD-1 and opioid receptor triple knockout mice) and men (healthy vol-
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unteers). In mice, we studied the effect of chronic and acute infusions of M6G against
a background of naltrexone or normal saline. In human volunteers, we tested the effect
of a bolus dose of M6G to a heat pain stimulus, in the presence of a continuous high
dose naloxone infusion or saline infusion. The results from the mice studies show that
acute and chronic injections of M6G cause hyperalgesia, both in naltrexone and saline
treated mice. Injection of NMDA-receptor antagonist MK-801 blocked and reversed
hyperalgesia in the chronic and the acute M6G treatment. The data from the human
volunteers indicate that M6G causes hyperalgesia after an acute injection, lasting more
than six hours. We can conclude that M6G induced hyperalgesia is independent of opi-
oid receptor activation and that a causal role for the NMDA receptor is indicated in
mice.
In Chapter 6, we undertook a literature search for all uses of naloxone in opioid ad-
diction. Naloxone is a non-selective, short-acting opioid receptor antagonist that has
a long clinical history of successful use and is presently considered a safe drug, even
at high doses (up to 10 mg). In opioid-dependent patients, naloxone is used in the
treatment of opioid-overdose induced respiratory depression, in (ultra)rapid detoxi-
fication and in combination with buprenorphine for maintenance therapy (to prevent
intravenous abuse). There are several risks related to naloxone use in opioid-dependent
patients. The induction of an acute withdrawal syndrome is is a potentially life threat-
ening one, due to possible occurrence of vomiting and aspiration. When used in the
treatment of opioid-induced respiratory depression, the effect of naloxone may wear
off prematurely and cause renarcotization and subsequent coma. The final risk is that
in patients treated for severe pain with an opioid, high-dose naloxone and/or rapidly
infused naloxone may cause catecholamine release and consequently pulmonary edema
and cardiac arrhythmias. These risks warrant the cautious use of naloxone, together





The data collected in this thesis show
• There is probably no separate M6G receptor in the respiratory system of the cat.
• M6G has its respiratory effects mainly on the central chemoreceptor and not on
the peripheral chemoreceptor in the respiratory system of the cat.
• Buprenorphine induced respiratory depression can be reversed using a continuous,
high dose infusion of naloxone.
• The reversal of buprenorphine’s respiratory effects by naloxone has an inverse
U-shaped dose-response curve.
• M6G and morphine’s respiratory effects are differently reversed by naloxone, in
both time of maximum reversal and duration of reversal.
• M6G induced hyperalgesia is independent of opioid receptor activation.





Al vele decennia vormen opiöıden de gouden standaard in behandeling van acute en
chronische pijn, ondanks de grote hoeveelheid bijwerkingen die ze veroorzaken. De
belangrijkste (want levensbedreigende) bijwerking is ademdepressie – een toestand die
gemakkelijk te verhelpen is door het gebruik van opiöıd-antagonisten. Naloxon is zo’n
middel – een kortwerkende opiöıd-antagonist met een hoge affiniteit voor de µ-opiöıd
receptor en een lagere affiniteit voor de κ- en δ-opiöıd receptoren. In hoofdstuk 2, 3 en
4 onderzochten we het gebruik van naloxon in door verschillende opiöıden veroorzaakte
ademdepressie.
In hoofdstuk 2 onderzochten we het bestaan van een specifieke morfine-6-glucuronide
(M6G) receptor door middel van 3-methoxy-naltrexon (3mNTX), een van naloxon af-
geleid geneesmiddel dat specifiek is voor de M6G-receptor. We vergeleken de adem-
halingseffecten van morfine en M6G in katten onder narcose door middel van de zoge-
heten ‘dynamic end-tidal forcing technique’ (DEF). Met deze techniek is het mogelijk
om onderscheid te maken tussen de CO2 gevoeligheid van de perifere en de centrale
chemoreflexbogen (Gp en Gc, respectievelijk). Deze variabelen zijn parameters in een
twee-compartimenten model voor het verband tussen CO2 en ademhaling. Hiertoe
werden drie verschillende studies uitgevoerd. In studie 1 werd het effect van achtereen-
volgens morfine, 3mNTX en M6G op de ademhaling gemeten. In studie werd het effect
van achtereenvolgens M6G, 3mNTX en morfine bekeken. Tenslotte werd in studie 3
het ademhalingseffect van 3mNTX alleen bekeken. Met deze studies werd aangetoond
dat zowel M6G als morfine de ademrespons op CO2 naar rechts verschuiven – er is een
hogere CO2 concentratie nodig om hetzelfde ademminuutvolume te bereiken. Uit de
studies bleek verder dat morfine met name de centrale chemoreflexboog remde, ter-
wijl M6G juist de perifere chemoreflexboog remde. Met 3mNTX was het mogelijk om
de ademdeprimerende effecten van beide opiöıden om te keren. Uit deze studies val-
len twee dingen te concluderen. Ten eerste hebben we gevonden dat in katten onder
narcose, de opiöıden M6G en morfine hun ademdeprimerende effect op verschillende
plaatsen binnen het ademhalingsregulatie systeem uitoefenen. Daarnaast kan geconclu-
deerd worden dat de verschillen in ademhalingseffect van morfine en M6G veroorzaakt
worden door een 3mNTX-sensitieve receptor, omdat 3mNTX de ademhalingseffecten
van beide opiöıden volledig omkeerde.
In hoofdstuk 3 onderzochten we in een grote groep gezonde vrijwilligers (n=67) de
ademhalingseffecten van buprenorfine, en de mogelijkheid om deze om te keren door
middel van naloxon. Het idee achter deze studie was dat de ademhalingseffecten van
buprenorfine schijnbaar moeilijk omkeerbaar zijn door naloxon. In dit hoofdstuk is data
uit drie verschillende onderzoeken gecombineerd. In al deze studies werd de ademha-
ling gemeten tegen een constante, verhoogde eind-expiratoire CO2-concentratie. In
het eerste onderzoek onderzochten we het effect van een intraveneuze bolus van 0.8
mg naloxon of van placebo (0.9% NaCl) op de ademhalingseffecten die door 0.2 mg
buprenorfine werden gëınduceerd. Deze dosis bleek onvoldoende om de ademdepressie
door buprenorfine om te keren. Daarom besloten we hierna een reeks van verschillende
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naloxon doseringen te testen (0.5 – 7 mg) die gegeven werden door middel van een
continu-infusie van 30 minuten. Met de informatie uit dit onderzoek onderzochten we
vervolgens het effect van een bolus naloxon in combinatie met een twee uur durende
continu-infusie op de ademhalingseffecten van 0.2 en 0.4 mg buprenorfine.
Een bolus naloxon is niet voldoende om de ademhalingseffecten van buprenorfine om te
keren, zo bleek uit het eerste onderzoek. In het tweede onderzoek ontdekten we dat een
dosis naloxon tussen de 2 – 4 mg wel volledige omkering van de ademhalingseffecten
kan geven. Een dosis hoger dan 5 mg bleek echter weer minder omkering te geven.
In de derde studie zagen we dat ademdepressie door buprenorfine omgekeerd kan wor-
den door een bolus naloxon, gevolgd door een continu-infusie naloxon van twee uur.
De belangrijkste conclusie uit dit onderzoek is dat omkering van door buprenorfine
veroorzaakte ademdepressie mogelijk is, maar dat het wel afhangt van de naloxon en
buprenorfine doseringen. Er lijkt een klokvormige curve (‘bell-shaped curve’) te zijn
voor omkering van buprenorfines ademhalingseffecten door naloxon (zie figuur 3.3), dus
een hogere naloxon dosering wil niet altijd zeggen dat er meer omkering is. Daarnaast
is het belangrijk om te beseffen dat de ademhalingseffecten van buprenorfine wellicht
langer aanwezig kunnen zijn dan dat de werking van naloxon aanhoudt, dus is een
continu-infusie van naloxon nodig voor het omkeren van de ademhalingseffecten van
buprenorfine.
In hoofdstuk 4 hebben we de effecten van naloxon op door M6G en morfine gëınduceer-
de ademdepressie gemodelleerd. Het betrof een studie in 56 gezonde vrijwilligers.
Eerst vergeleken we de effecten van 400 µg naloxon en placebo (0.9% NaCl) op de
ademhalingseffecten van morfine en M6G. Vervolgens onderzochten we verschillende
andere doseringen (200 µg in de morphine groep, 25 and 100 µg in de M6G groep)
in beide opiöıden. Het effect op de ademhaling werd steeds getest bij een constante
eind-expiratoire CO2 concentratie. De effecten van morfine bleken snel om te keren
en kortdurend, terwijl de effecten van naloxon in de M6G-groep langer op zich lieten
wachten: de tijd tot het maximale effect was bereikt was veel langer in de M6G groep
(45 minuten vergeleken met 13 minuten in de morfine groep) en als maximale omke-
ring was bereikt, hield deze ook veel langer aan (tot wel 90 minuten). We fitten een
farmacokinetisch/farmacodynamisch model op de data en hierin vallen twee dingen
op. Ten eerste was de invoering van een extra parameter, γ, nodig voor een adequaat
model van onze data. Daarnaast vonden we een verschil in de naloxon C50 tussen de
morfine en de M6G groepen. Dit betekent dat naloxon een verschillende potentie heeft
voor de omkering van de ademhalingseffecten van beide opiöıden (er is minder naloxon
nodig om de ademhalingseffecten van M6G om te keren dan voor de omkering van
de ademhalingseffecten van morfine). De conclusie die vervolgens te trekken valt is
dat de ademhalingseffecten van morfine en M6G verschillend worden omgekeerd door
naloxon. Het blijft speculatie, maar het meest waarschijnlijk is dat deze verschillen
worden veroorzaakt doordat naloxon niet alleen effecten heeft op de µ-opiöıd receptor
zelf, maar ook verder in de signaleringscascade van de ademhalingsregulatie.
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De omkering van opiöıd-gëınduceerde ademdepressie is echter niet de enige toepassing
van naloxon. Hoofdstukken 5 en 6 gaan in op ander gebruik van naloxon, te weten in
hyperalgesie (Hoofdstuk 5) en in opiöıd-verslaving (Hoofdstuk 6).
Hyperalgesie veroorzaakt door opiöıden is pas recent onder de aandacht van onderzoe-
kers gekomen. Het wordt waarschijnlijk veroorzaakt door activatie van de N-methyl-D-
aspartaat receptor of NMDA-receptor, die op zijn beurt weer geactiveerd zou kunnen
worden door µ-opiöıd receptor activatie. In hoofdstuk 5 hebben we deze hypothese
onderzocht in muizen en in gezonde vrijwilligers. In muizen bestudeerden we het effect
van korte en langdurige M6G infusies tegen een achtergrond van naltrexon of 0.9%
NaCl. In gezonde vrijwilligers onderzochten we het effect van een bolus dosis M6G
op een hittepijntest, ook weer tegen een achtergrond van naloxon of 0.9% NaCl. De
resultaten van de muizenstudies laten zien dat zowel korte als langdurige infusies van
M6G hyperalgesie veroorzaken, en dat het niet uitmaakt of er naltrexon of zoutoplos-
sing op de achtergrond werd gegeven. Toediening van de NMDA receptor antagonist
MK-801 verhinderde het ontstaan van hyperalgesie en zorgde voor een omkering van
hyperalgesie in zowel de korte als de langdurige M6G toediening. De resultaten van de
vrijwilligers laten zien dat M6G ook in mensen een hyperalgetisch effect heeft, dat in
ieder geval zes uur duurt. Ook hier is er geen invloed van het al dan niet toevoegen van
naloxon. We kunnen daarom concluderen dat M6G hyperalgesie veroorzaakt en dat
dit onafhankelijk is van opiöıd-receptor activatie. In de muizenstudie werd aangetoond
dat er een belangrijke rol is voor de NMDA receptor in het ontstaan van hyperalgesie
na opiöıd-toediening.
In hoofdstuk 6 tenslotte zijn de resultaten van een literatuuronderzoek naar het gebruik
van naloxon in opiöıd-verslaving samengevoegd. Naloxon is een niet-selectieve, kort-
werkende opiöıd-antagonist die reeds lang met succes in de klinische praktijk toegepast
wordt. Het wordt beschouwd als een veilig middel, zelfs bij hoge doseringen (tot en
met 10 mg). In opiöıd-verslaafde patiënten wordt naloxon gebruikt in de behandeling
van ademhalingsdepressie als gevolg van een overdosis opiöıden, in snelle ontwenning
en in combinatie met buprenorfine voor langdurige onderhoudstherapie (waarbij de na-
loxon intraveneus misbruik moet voorkomen). Er zijn verschillende risico’s verbonden
aan het gebruik van naloxon in opiöıd-verslaafde patiënten, waarbij de belangrijkste
het ontstaan van een acuut ontwenningssyndroom is. Hierbij is met name het optre-
den van braken en het daarmee gepaard gaande risico op aspiratie van maaginhoud
gevaarlijk. Als naloxon gebruikt wordt voor de behandeling van ademdepressie door
een overdosis bestaat de kans dat de effecten van naloxon te snel afnemen, waardoor
er opnieuw sedatie en zelfs coma kan ontstaan. Ten slotte is bekend dat in patiënten
die voor ernstige pijn met opiöıden behandeld werden, een te snelle of te hoge dose-
ring van naloxon een catecholamine-release kan veroorzaken, die vervolgens weer kan
leiden tot longoedeem en hartritmestoornissen. Gezien deze risico’s is het belangrijk
om naloxon voorzichtig te gebruiken en waar nodig de cardiale en pulmonale toestand




Uit de gegevens in dit proefschrift is het volgende te concluderen:
• Er is waarschijnlijk geen aparte M6G receptor in het ademhalingscentrum van
de kat.
• M6G oefent zijn ademhalingseffecten voornamelijk uit binnen de centrale chemo-
reflexboog, en niet op de perifere chemoreflexboog, in het ademhalingsregulatie-
systeem van de kat.
• Door buprenorfine gëınduceerde ademhalingsdepressie kan worden omgekeerd
door een hoge dosering naloxon in een continu infusie.
• Er is sprake van een klokvormige curve bij de omkering van de ademhalingseffec-
ten van buprenorfine door naloxon.
• De omkering van ademhalingseffecten van M6G and morfine door naloxon ver-
schillen zowel in de tijdsduur tot het maximale omkeringseffect is bereikt, als in
de duur van de omkering.
• Door M6G veroorzaakte hyperalgesie is onafhankelijk van opiöıd-receptor activa-
tie.
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